BioAv Cancer Research Results

BioAv, bioavailability: Click to Expand ⟱
Source:
Type: measurement
Bioavailability (usually in %) absorbed by the body.


Scientific Papers found: Click to Expand⟱
6461- 1,8-Cin,    1,8-cineole (eucalyptol): A versatile phytochemical with therapeutic applications across multiple diseases
- Review, AD, NA - Review, Var, NA
*Inflam↓, long history of use in traditional medicine and exhibits an array of biological properties, including anti-inflammatory, antioxidant, antimicrobial, bronchodilatory, analgesic, and pro-apoptotic effects.
*antiOx↑,
*neuroP↑, recent studies have highlighted the neuroprotective, analgesic, and pro-apoptotic properties of 1,8-cineole, underscoring its potential beneficial role in a broad spectrum of conditions such as Alzheimer’s disease, neuropathic pain, and cancer
*BioAv↑, Marked by a logP value of 2.74, 1,8-cineole strikes an optimal equilibrium between solubility and permeability, hinting at its favorable potential for oral bioavailability
*Half-Life↝, In rabbits, oral administration of 200 mg/kg has led to rapid attainment of peak plasma concentration within 1 h, indicating efficient absorption
*toxicity↓, compound’s toxicity profile, the oral acute LD50 value in rats is documented at 2480 mg/kg body weight
*PGE2↓, 1,8-cineole decreased the release of prostaglandin E2 and leukotriene B4 (LTB4) from peripheral blood mononuclear cells in asthmatic patients, and reduced TNF-α, IL-1β, LTB4, and thromboxane B2 in lipopolysaccharide (LPS)-stimulated peripheral blo
*TNF-α↓,
*IL1β↓,
*NO↓, 1,8-cineole hindered LPS-induced nitric oxide (NO) production in mouse macrophage cell lines
*NF-kB↓, inhibition of nuclear translocation of NF-κB p65 and PPARγ, leading to the suppression of immune response genes.
*PPARγ↓,
COX2/PTGS2↓, ,8-cineole has been found to impede UVB-induced COX-2 protein and mRNA production in HaCaT cells
*ROS↓, 1,8-cineole’s antioxidant properties play a crucial role in its therapeutic potential, as it is effective in neutralizing reactive oxygen species (ROS)
*SOD↑, 1,8-cineole treatment enhanced antioxidant enzymes activities, such as superoxide dismutase (SOD) and catalase (CAT), increased total antioxidant capacity, and decreased ROS and malondialdehyde (MDA)
*Catalase↑,
*TAC↑,
*MDA↓,
*lipid-P↓, 1,8-cineole has demonstrated the ability to inhibit LP
*NRF2↑, The antioxidant activity of 1,8-cineole is mediated, in part, by activating the Nrf2/Keap1 system
*HO-1↑, increased expression of phase II detoxifying enzymes and antioxidant proteins, such as heme oxygenase-1 and NAD(P)H: quinone oxidoreductase 1 (NOQ1)
*NADPH↑,
*GPx↑, 1,8-cineole treatment has been shown to enhance the activities of antioxidant enzymes, such as SOD, GPx, and CAT,
*AntiBio↑, Antibacterial properties: activity, synergy with antibiotics, and impact on biofilm formation and cell morphology
*Synergy↑, Although 1,8-cineole exhibited weaker bactericidal activity than commonly used antibiotics such as gentamicin and amoxicillin (AMX)/clavulanic acid, it significantly reduced the minimum inhibitory concentration of antibiotics when used in combination
*AntiFungal↑, Antifungal properties: inhibition of fungal growth and disruption of biofilm formation
*AntiViral↑, Antiviral properties: inhibition of viral replication and enhancement of antiviral responses
*TRPA1↑, 1,8-cineole could activate TRPA1 channels in the dorsal root ganglia (DRG),
Synergy↑, when combined with simvastatin, increased G0/G1 cell cycle arrest and sensitized cells to apoptosis
TumCCA↑, 1,8-cineole induced G0/G1 arrest and senescence in HepG2 cells through oxidative stress and various signaling pathways such as MAPK, AMPK, and Akt/mTOR
ROS↑,
MAPK↝,
mTOR↝,
Apoptosis↑, HCT116 and RKO human colon cancer cell lines, 1,8-cineole selectively promoted apoptosis rather than necrosis
survivin↓, This process was linked to survivin and Akt inactivation, along with p38 activation.
Akt↓,
p38↑,
cl‑PARP↑, triggered subsequent cleavage of PARP and caspase-3, resulting in apoptosis.
cl‑Casp3⇅,
P53↑, increasing p53 expression, as well as the expression of apoptotic proteins (Bax/Bcl-2, Cyt-c, caspase-9, and caspase-3)
BAX↑,
Cyt‑c↑,
Casp9↑,
Dose↝, efficacious concentrations of 1,8-cineole reported for inhibiting in vitro cancer cell proliferation range from micromolar [135], [136] to millimolar (mM)
*Aβ↓, 1,8-cineole in rat PC12 cells (pheochromocytoma cells) demonstrated effective mitigation of the Aβ induced cytotoxicity and oxidative stress
*tau↓, 1,8-cineole has shown the ability to modulate tau phosphorylation by suppressing GSK-3β activity and to reduce Aβ production by inhibiting beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1), both in vitro and in vivo
*GSK‐3β↓,
*BACE/β-secretase↓,
*cardioP↑, 1,8-cineole enhanced cell viability, inhibited cardiac hypertrophy, attenuated cardiac remodeling, improved cardiac function, and decreased the concentrations of atrial natriuretic peptide and brain natriuretic peptide in rat hearts
MFN2↑, 1,8-cineole was also found to inhibit the activation of dynamin-related protein 1 and promote mitochondrial fusion by increasing MFN2.
*antiAll↑, demonstrated in clinical trials involving patients with respiratory disorders, including chronic obstructive pulmonary disease, asthma,

6469- 1,8-Cin,    Pharmacokinetic Studies of the Fragrance Compound 1,8-Cineol in Humans during Inhalation
- Human, Nor, NA
*BioAv↑, 1,8-cineol is well absorbed from breathing air, with a peak plasma concentration after ∼18 min.
*Half-Life↝, The elimination of this fragrance compound from the blood is biphasic, with a mean distribution half-life of 6.7 min and an elimination half-life of 104.6 min.

6462- 1,8-Cin,    Modes of Action of 1,8-Cineol in Infections and Inflammation
- Review, Var, NA - Review, AD, NA
*BioAv↑, become increasingly clear in the recent years that 1,8-Cineol spreads almost everywhere in the human body after its oral administration, from the gut to the blood to the brain.
*BBB↑,
*AntiViral↑, anti-viral effects have been observed to include numerous bacteria and fungi species.
*Bacteria↓,
*AntiFungal↑,
*Inflam↓, central mode of action of 1,8-Cineol is the inhibition of pro-inflammatory cytokine expression
*BioAv↑, 1,8-Cineol was detectable in nasal tissue samples after its oral administration for 14 days, which indicates the systemic distribution of 1,8-Cineol via the gut and the blood stream
*MUC2↓, significantly reduced expression levels of the mucin genes MUC2 and MUC19 in close association with a significantly attenuated activity of transcription factor NF-κB
*MUC19↓,
*NF-kB↓, reduced the expression levels of transcriptional activator nuclear factor (NF)-kB p65 and expression of intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 in lung tissues
*ICAM-1↓,
*VCAM-1↓,
DNAdam↑, colon cancer cells on the potential genotoxicity of 1,8-Cineol revealed a concentration-dependent increase in oxidative DNA damage, whereas it did not affect the cell viability due to DNA repair mechanisms
*lipid-P↓, suppressing the expression of lipid mediators and prostaglandin D2
*PGE2↓,
*IL4↓, decreased expression levels of different inflammatory cytokines such as interleukin (IL)-4, IL-6 and granulocyte macrophage colony stimulating factor (GM-CSF) in bronchial epithelial cells
*IL6↓,
*IL1β↓, 1,8-Cineol-containing leaf extracts significantly suppressed the expression of pro-inflammatory cytokines IL-1β and IL-6 [
*IL6↓,
Synergy↑, 1,8-Cineol in combination with ellagic acid has been shown to downregulate different cytokines such as transforming growth factor beta-1 (TGF-β1), Fascin-1 (FSCN1), vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) in p
TGF-β↓,
fascin↓,
VEGF↓,
MMP9↓,
*MAPK↓, 1,8-Cineol was shown to suppress the activation of the MAPK/ERK
*ERK↓,
JNK↓, decreased activities of transcription factor NFκB and the JNK (c-Jun N-terminal kinase)/AP-1 (activator protein-1) pathway in the human cancer cell lines U373 and HeLa in response to 1,8-Cineol, the active ingredient of the drug Soledum
Wnt↓, 1,8-Cineol acts as an inhibitor of the Wnt/β-catenin pathway in head and neck squamous cell carcinoma (HNSCC).
β-catenin/ZEB1↓,
GSK‐3β↑, decreased inhibition of glycogen synthase kinase 3 (GSK-3) and reduced levels of WNT11
*neuroP↑, 1,8-Cineol has been shown to have neuroprotective activity.
*GSK‐3β↓, decreased activity of GSK-3 in response to 1,8-Cineol could ameliorate advanced glycation end products,
*AGEs↓,
*BBB↑, eucalyptol reveals an opening effect on the blood–brain barrier
*NLRP3↓, controls inflammation by suppressing the NOD-like receptor pyrin domain-containing 3 (NLRP3) activation

6470- 1,8-Cin,    Determination of orally administered 1,8-Cineol in nasal polyp tissues from chronic rhinosinusitis patients using gas chromatography: mass spectrometry
- Human, Nor, NA
*BioAv↑, Our data indicate a systemic distribution of 1,8-Cineol in the human body after its oral administration.

5272- 3BP,    The efficacy of the anticancer 3-bromopyruvate is potentiated by antimycin and menadione by unbalancing mitochondrial ROS production and disposal in U118 glioblastoma cells
- in-vitro, GBM, U87MG - in-vitro, Nor, HEK293
Glycolysis↓, We used the antiglycolytic 3-bromopyruvate (3BP) as a metabolic modifier to treat U118 glioblastoma cell
ROS↑, ROS generated in mitochondria were enhanced at 30 μM 3BP, possibly by unbalancing their generation and their disposal because of glutathione peroxidase inhibition.
GPx↓,
eff↓, Indeed, the scavenger of mitochondrial superoxide MitoTEMPO counteracted 3BP-induced cyt c release and weakened the potentiating effect of 3BP/
OXPHOS↓, (3BP) is a reactive non-specific drug that can act as a metabolic modifier by interfering with glycolysis and oxidative phosphorylation in cancer cells
HK2↓, The mitochondrial hexokinase-II is the main target since its activity is specifically blocked by the formation of a pyruvinyl adduct after reacting with 3BP at the surface of the outer mitochondrial membrane
ATP↓, In malignant tumour cell lines, 3BP inhibits ATPase activity, reduces ATP levels, and reverses chemoresistance by antagonizing drug efflux by acting on the ATP-binding cassette transporters (
ROS↑, Furthermore, 3BP increases the production of reactive oxygen species (ROS) (Ihrlund et al., 2008; Kim et al., 2008; Macchioni et al., 2011a), induces ER stress,
ER Stress↑,
BioAv↓, Unfortunately, prolonged treatment with the drug reduces ROS levels and confers resistance by inducing regulatory genes that act on antioxidant systems.
Cyt‑c↑, 3BP induces cytochrome c release without triggering an apoptotic cascade in U118 cells
Synergy↑, The ROS enhancers antimycin and menadione sensitize U118 cells to 3BP

5260- 3BP,    Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
- in-vivo, PC, NA
TumCG↓, In vivo, animals treated with β-CD–3-BrPA demonstrated minimal or no tumor progression as evident by the BLI signal
toxicity↓, In contrast to animals treated with free 3-BrPA, no lethal toxicity was observed for β-CD–3-BrPA.
BioAv↝, It is possible that in the microencapsulated formulation, 3-BrPA, is more bioavailable for uptake into tumor cells and less available to the normal cells that apparently mediate its toxicity
GAPDH↓, 3-Bromopyruvate (3-BrPA), a highly potent small-molecular inhibitor of the enzyme GAPDH, represents the only available antiglycolytic drug candidate that is able to enter cancer cells selectively through the monocarboxylate transporter 1 (MCT1; refs.
toxicity↑, However, due to its alkylating properties, 3-BrPA is associated with significant toxicity when delivered systemically in therapeutic doses, which has impeded the clinical development and use of this drug in patients with cancer
Dose↝, Encapsulation of 3-BrPA in β-CD was achieved by portionwise addition of 3-BrPA (166 mg, 1 mmol/L) to a stirring solution of β-CD (1,836 mg in 30 mL DI water). The resulting solution was sonicated for 1 hour at room temperature and then shaken overnig
ATP↓, ability of microencapsulated 3-BrPA (β-CD-3-BrPA) to achieve dose-dependent ATP depletion and cell death, two human pancreatic cancer cell lines were employed.
eff↑, both PDAC cell lines were more sensitive to the drugs when hypoxic (Fig. 2)
TumCI↓, MiaPaCa-2 and Suit-2 cells showed a reduction in invasion at drug concentrations as low as 12.5 µmol/L.
MMP9↓, marked reduction in the secretion of MMP-9 was detected in both cell lines.
toxicity↓, No organ toxicities or tissue damage was observed in animals treated with β-CD–3-BrPA

3537- 5-HTP,    5-Hydroxytryptophan: a clinically-effective serotonin precursor
- Review, Nor, NA
*5HT↑, effective serotonin precursor
*BioAv↑, 5-HTP is well absorbed from an oral dose, with about 70 percent ending up in the bloodstream.
*BBB↑, It easily crosses the blood-brain barrier and effectively increases central nervous system (CNS) synthesis of serotonin

5309- 5-HTP,    Effects of Carbidopa on the Cerebral Accumulation of Exogenous L-5-Hydroxytryptophan in Mice
- in-vivo, Nor, NA
*BioAv↑, Carbidopa, an extracerebral inhibitor of L-aromatic amino acid decarboxylation, increased dose dependently the brain bioavailability of systemically administered 5-HTP

5298- 5-HTP,    Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa
- Human, AD, NA
*BioAv↑, By combining 5-HTP with carbidopa (CBD), increased bioavailability for brain penetration and decreased peripheral side effects would be expected, due to reduced peripheral decarboxylation of 5-HTP to 5-HT
*Dose↝, he tolerability and subjective effects of oral 5-HTP at 100, 200 and 300 mg combined with CBD and the pharmacokinetic properties of the 5-HTP/CBD-challenge.
*toxicity↝, Frequent occurrence of nausea and vomiting limits the applicability of this challenge at 5-HTP doses above 100 mg.

5291- 5-HTP,    Kinetics of l-5-hydroxytryptophan in healthy subjects
- in-vivo, Nor, NA
*Half-Life↝, biological half-life of 5-HTP ranged from 2.2 to 7.4 hours, and the plasma clearnce ranged from 0.10 to 0.23 1/kg/hour.
*BioAv↑, The bioavailability of 5-HTP after oral administration in combination with carbidopa was calculated as 48% ± 15 (mean ± SD). T

9261- Acai, EO,    Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp (Euterpe oleracea Mart.) in human healthy volunteers
- Study, Nor, NA
*Dose?, Healthy volunteers (12) were dosed at 7 mL/kg of body weight after a washout phase and overnight fast, and plasma was repeatedly sampled over 12 h and urine over 24 h after consumption.
*BioAv↝, total anthocyanins quantified as cyanidin-3-O-glucoside showed Cmax values of 2321 and 1138 ng/L at t max times of 2.2 and 2.0 h, and AUC last values of 8568 and 3314 ng h L(-1) for pulp and juice, respectively.
*eff↑, plasma antioxidant capacity of up to 2.3- and 3-fold for acai juice and pulp, respectively were observed

5457- AF,    Clinical pharmacokinetics of oral and injectable gold compounds
- Human, Nor, NA
*BioAv↝, intramuscularly administered gold is greater than 95% bioavailable, whereas only 20 to 30% of an orally administered dose of auranofin is absorbed.
*Dose↝, 50mg intramuscular injection of GST, serum gold concentrations rise sharply, peaking between 4 and 8 mg/L in approximately 2 hours and declining to an average of 3 mg/L by 7 days.
*Half-Life↑, Both compounds are retained within the body for prolonged periods.
*BioAv↝, In human subjects, parenterally administered gold is widely distributed among bodily tissues, showing a predilection for tissues of the reticuloendothelial system as well as the kidney and adrenal cortex.
*other↝, auranofin but animal studies have shown comparatively less affinity for the liver, kidney and spleen.

5464- AF,    Inhibition of Thioredoxin-Reductase by Auranofin as a Pro-Oxidant Anticancer Strategy for Glioblastoma: In Vitro and In Vivo Studies
- vitro+vivo, GBM, NA
TrxR↓, Gold derivatives are irreversible inhibitors of TrxR. Among them, auranofin (AF), a selective TrxR inhibitor, has proven its effectiveness as a drug for the treatment of rheumatoid arthritis
BioAv↓, further clinical application of AF could be challenging due to the low solubility and insufficient delivery to glioblastoma.
ROS↑, The inhibition of TrxR1, which leads to increased ROS levels, is currently recognized as the primary mechanism of AF cytotoxicity [106]. In vitro studies have also shown that AF inhibits other thioredoxin reductases, such as TrxR2 and TrxR3
eff↝, The literature indicates that not all cancer tumors exhibit the same level of TrxR expression, affecting their sensitivity to AF.
TET1?, AF was shown to inhibit TET1 in T-ALL models
CompStab↑, Encapsulating AF into nanoparticles or combining it with other pharmaceutical excipients can minimize its potential adverse effects, preserve its interaction with serum proteins, and result in greater stability.

5434- AG,    Recent Advances in the Mechanisms and Applications of Astragalus Polysaccharides in Liver Cancer Treatment: An Overview
- Review, Liver, NA
AntiCan↑, Preclinical studies indicate that APS exerts significant anti-liver cancer effects through multiple biological actions, including the promotion of apoptosis, inhibition of proliferation, suppression of epithelial–mesenchymal transition, regulation of
Apoptosis↑,
TumCP↓,
EMT↓,
Imm↑, improving host immune response
ChemoSen↑, APS exhibits synergistic effects when combined with conventional chemotherapeutics and interventional treatments such as transarterial chemoembolisation, improving efficacy and reducing toxicity.
BioAv↓, limitations such as low bioavailability and a lack of large-scale clinical trials remain challenges for clinical translation.
TumCG↓, APS significantly inhibited tumour growth in H22-bearing mice with a dose-dependent effect (100, 200, 400 mg/kg), with the 400 mg/kg group achieving a tumour inhibition rate of 59.01%
IL2↑, APS enhance the thymus and spleen indices and elevates the key cytokines, including IL-2, IL-12, and TNF-α.
IL12↑,
TNF-α↑,
P-gp/ABCB1↓, APS reversed chemoresistance by downregulating P-glycoprotein and MDR1 mRNA expression
MDR1↓,
QoL↑, These effects contributed to improved treatment tolerance and enhanced quality of life [39].
Casp↑, APS can activate both the intrinsic and extrinsic apoptotic pathways, leading to caspase activation and DNA fragmentation
DNAdam↑,
Bcl-2↓, Mechanistically, APS downregulate antiapoptotic proteins such as Bcl-2 while upregulating proapoptotic proteins such as Bax and cleaved caspase-3.
BAX↑,
MMP↓, APS have been shown to disrupt the mitochondrial membrane potential and promote the release of cytochrome c, thereby enhancing apoptotic cascades in hepatocellular carcinoma models.
Cyt‑c↑,
NOTCH1↓, APS (0.1, 0.5, and 1.0 mg/mL) were shown to reduce both mRNA and protein levels of Notch1 in a concentration-dependent manner.
GSK‐3β↓, APS significantly inhibited the proliferation of HepG2 cells by downregulating the expression of glycogen synthase kinase-3β (GSK-3β), with 200 μg/mL being the most effective concentration.
TumCCA↑, APS exerted these effects by inducing cell cycle arrest at the G2/M and S phases, thereby impeding tumour cell proliferation [35].
GSH↓, HepG2 cells. APS also reduced intracellular glutathione (GSH) levels, increased reactive oxygen species (ROS) and lipid peroxidation levels, and elevated intracellular iron ion concentrations—all in a dose-dependent manner.
ROS↑,
lipid-P↑,
c-Iron↑,
GPx4↓, APS treatment led to the downregulation of GPX4 and upregulation of ACSL4, indicating that APS promotes ferroptosis in liver cancer cells.
ACSL4↑,
Ferroptosis↑,
Wnt↓, inhibit the expression of key proteins involved in the Wnt/β-catenin signalling pathway
β-catenin/ZEB1↓,
cycD1/CCND1↓, by downregulating the key oncogenic targets, including β-catenin, C-myc, and cyclin D1, which subsequently reduces Bcl-2 expression and activates the apoptotic cascade in HepG2 liver cancer cells.
Akt↓, It also inhibited the Akt/p-Akt signalling pathway.
PI3K↓, APS inhibit the PI3K/AKT/mTOR signalling pathway, which is a central negative regulator of autophagy.
mTOR↓,
CXCR4↓, PS upregulated the epithelial marker E-cadherin while downregulating the mesenchymal marker vimentin and the chemokine receptor CXCR4 at both mRNA and protein levels, suggesting that APS suppress liver cancer cell growth and metastasis by inhibiting
Vim↓,
PD-L1↓, APS interfere with immune checkpoint signalling by downregulating Programmed death-ligand 1 (PD-L1) expression on tumour cells.
eff↑, The preparation of polysaccharide–SeNP composites typically involves using sodium selenite (Na2SeO3) as the precursor and ascorbic acid (Vc) as the reducing agent, with synthesis carried out via a chemical reduction method in a polysaccharide solutio
eff↑, Mechanistic investigations revealed that AASP–SeNPs elevated intracellular ROS levels and reduced the mitochondrial membrane potential (∆Ψm).
ChemoSen↑, APS enhance doxorubicin-induced endoplasmic reticulum (ER) stress by reducing O-GlcNAcylation levels, thereby promoting apoptosis of liver cancer cells.
ChemoSen↑, APS inhibited BEL-7404 human liver cancer cell growth in a concentration-dependent manner and showed stronger cytotoxicity when combined with cisplatin.
chemoP↑, APS protects against chemotherapy-induced liver injury, particularly that caused by CTX, through antiapoptotic mechanisms

5439- AG,    Absorption enhancement study of astragaloside IV based on its transport mechanism in Caco-2 cells
- in-vitro, Colon, Caco-2
BioAv↑, Both chitosan and sodium deoxycholate can increase the permeation efficiency of astragaloside IV.
BioAv↓, This study indicated that astragaloside IV having a low fraction dose absorbed in humans mainly due to its poor intestinal permeability, high molecular weight, low lipophilicity as well as its paracelluar transport may directly result in the low perm

4600- AgNPs,    Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model
- in-vivo, Nor, NA
*Half-Life↝, Fecal silver began to decline at 12 h for all the AgNPs and was at baseline levels by 48 h.
*toxicity↓, Acute ingestion of AgNP is well-tolerated at high doses, irrespective of size or coating
*Dose↑, The doses utilized in this study (0.1, 1 and 10 mg/kg bw/d) were equivalent to, respectively, 20×, 200× and 2000× the EPA oral reference dose (RfD, 0.005 mg/kg bw/d) for silver
*other↝, Previous estimates of colloidal silver doses associated with clinically evident argyria range between 40× and 700× the oral RfD, although these typically represent repeated exposures
*eff↝, Acute ingestion of AgNP is well-tolerated with concurrent antibiotic administration
*BioAv↓, Oral bioavailability was previously determined as low (4.2%) for a single 10 mg/kg bw dose of 7.9 nm AgNP-citrate in rats

4598- AgNPs,    In vivo human time-exposure study of orally dosed commercial silver nanoparticles
- in-vivo, Nor, NA
*toxicity∅, concluding no detectable toxicity
*Dose↝, 10 ppm oral silver particle dosing [36 subjects] and 32 ppm oral silver particle dosing [24 subjects]). 100 μg/day for 10 ppm, and 480 μg/day for 32 ppm silver
*Dose↝, corresponding to ionic silver comprising some 84.3% of the total silver content in the product administered orally to patients.
*BioAv↝, Peak serum silver concentration was detected in 42% of subjects in the 14-day 10 ppm dosing showing a mean of 1.6±0.4 mcg/L
*BioAv↝, The 32 ppm dose mean concentration was detected in 92% of subjects at 6.8±4.5 mcg/L
*H2O2∅, No statistically significant change in markers of hydrogen peroxide production or peroxiredoxin protein expression were detected.
*IL8∅, Analysis of IL-8, IL-1α, IL-1β, MCP1 and NQO1 also showed no statistical difference between the active silver and placebo solutions.
*IL1α∅,
*IL1β∅,
*MCP1/CCL2∅,
*NQO1∅,
*BioAv↓, miniscule (<1%) amounts of 10-nm gold nanoparticles permeate across the gut to enter systemic vascular circulation from the intestine in rodents.51 We assert that silver metallic particle absorption is similar

4595- AgNPs,    ORAL DELIVERY OF SILVER NANOPARTICLES – A REVIEW
- Review, Nor, NA
*BioAv↝, absorption rangesfrom 0.4% to 10% depending at the species, such as 10% and 6% for dogs and monkeys, respectively [31

4594- AgNPs,  Citrate,    Bioavailability and Toxicokinetics of citrate-coated silver nanoparticles in rats
- in-vivo, Nor, NA
*BioAv↓, bioavailability of orally administered AgNPs was 1.2% in the group treated with 1 mg/kg AgNPs and 4.2% in the group treated with 10 mg/kg AgNPs.

9311- AgNPs,    Silver Nanoparticles as Anticancer Agents: Mechanisms Insight, Current Studies, and Limitations
- Review, Var, NA
*Bacteria↓, In addition to their well-known antibacterial, antioxidant, and anti-inflammatory properties, AgNPs also exhibit anticancer properties.
*antiOx↑,
*Inflam↓,
*AntiCan↑,
ROS↑, AgNPs exert significant anticancer effects through multiple mechanisms, including oxidative stress, mitochondrial dysfunction, DNA damage, cell cycle arrest, and apoptosis.
mtDam↑,
DNAdam↑,
TumCCA↑,
Apoptosis↑,
eff↑, green-synthesized AgNPs often exhibit enhanced biocompatibility and improved selective cytotoxicity against cancer cells.
selectivity↑, Selectivity, that is, the most critical property underlying anticancer activity, is defined as the observation that AgNPs have a much greater toxic effect on cancer cells than on healthy cells [13]
Synergy↑, . It is widely accepted that AgNPs capped with plant extracts, microbial metabolites, or polyphenols exhibit much more selective toxicity than traditionally synthesized AgNPs
EPR↑, selectivity arises because the abnormal metabolism of cancer cells enables higher uptake of AgNPs,
eff↑, Particularly, small-sized AgNPs demonstrate enhanced ability to trigger apoptosis, necrosis, or autophagy in cancer cells, leading to effective tumor cell eliminatio
Cyt‑c↑, Figure 1
Casp↑, AgNPs induce apoptosis in cancer cells through the p53/bax/bcl-2 and caspase-3 pathways
Bcl-2↓, Bcl-2 gene was reported to be suppressed, while the BAX gene was significantly increas
BAX↑,
P53↑, Caspase-3 and p53 proteins were observed to increase by 203% and 109%
Synergy↑, anticancer activity of epirubicin-coated AgNPs tested the synergistic effects of AgNPs with the chemotherapeutic agent epirubicin
PI3K↓, Reported significant inhibition of the PI3K/AKT signaling pathway, which plays a key role in cell proliferation.
Akt↓,
Synergy↑, synthesized AgNPs using extracts from Cucurbita maxima, Moringa oleifera, and Acorus calamus and evaluated their cytotoxic effects against A431 epidermoid carcinoma cells
toxicity↝, the same effects can also lead to organ damage and other toxic effects when applied to healthy cells.
BioAv↝, Therefore, rapid clearance from circulation, strong retention in RES organs, and low accumulation in target tissues are the main pharmacokinetic challenges that limit the clinical efficacy of AgNPs

305- AgNPs,    Activity and pharmacology of homemade silver nanoparticles in refractory metastatic head and neck squamous cell cancer
- Case Report, HNSCC, NA
OS↑, remission
Dose↓, Electron microscopy of AgNP solution revealed bimodal nanoparticle size distribution: 3 and 12 nm.
BioAv↝, basal **silver ion** concentrations of 32 ng/g, rising to 46 ng/g 1 hour after ingesting 60 mL of AgNP solution.
toxicity↓, no toxicities were observed and he had complete radiographic resolution of his cancer
Remission↑,
other↝, patient serum was analyzed and intact nanoparticles were not identified. Thus, we could not isolate the circulating AgNP form
other↝, Analysis of urine showed no AgNP or detectable nanoparticle fragments
other↝, AgNP solution was also exposed to simulated gastric fluid, in which they aggregated into larger nanoparticles according to UV-Vis absorption.
Dose↝, GDH: based on repeat setup, estimated PPM is 20PPM assuming 67% effecient. 1.2mg/60mL (he took 160mL/day
BioAv↝, GDH: chatAI computed the estimated bioavailability at 7%

9220- AITC,    Allyl isothiocyanate arrests cancer cells in mitosis, and mitotic arrest in turn leads to apoptosis via Bcl-2 protein phosphorylation
- in-vitro, Bladder, NA
TumCCA↑, Here, we show that AITC arrests human bladder cancer cells in mitosis and also induces apoptosis.
mitA↑,
Apoptosis↑,
α-tubulin↓, Mitotic arrest by AITC was associated with increased ubiquitination and degradation of α- and β-tubulin.
Cyt‑c↑, AITC induced mitochondrion-mediated apoptosis, as shown by cytochrome c release from mitochondria to cytoplasm, activation of caspase-9 and caspase-3, and formation of TUNEL-positive cells.
Casp9↑,
Casp3↑,
JNK↑, AITC activates JNK
AntiBio↑, Allyl isothiocyanate (AITC)2 is a naturally occurring compound that possesses both antimicrobial and anticancer activities
AntiCan↑,
BioAv↑, Bioavailability of AITC is extremely high; nearly 90% of orally administered AITC is absorbed

9221- AITC,    Inhibition of bladder cancer development by allyl isothiocyanate
- vitro+vivo, Bladder, NA
TumCP↓, allyl isothiocyanate (AITC), an ingredient of many common cruciferous vegetables, potently inhibited the proliferation of bladder carcinoma cell lines in vitro [half maximal inhibitory concentration (IC50) of 2.7–3.3 μM],
TumCCA↑, which was associated with profound G2/M arrest and apoptosis.
Apoptosis↑,
selectivity↑, In contrast, AITC was markedly less toxic to normal human bladder epithelial cells (IC50 of 69.4 μM).
eff↝, low oral dose of AITC (1 mg/kg) significantly inhibited the development and muscle invasion of the orthotopic bladder cancers but was ineffective against the subcutaneous xenografts of the same cancer cells in the same animals.
BioAv↝, This differential effect was explained by our finding that urinary levels of AITC equivalent were two to three orders of magnitude higher than that in the plasma and that its levels in the orthotopic cancer tissues were also three orders of magnitude

9227- AITC,    Allyl isothiocyanate and its N-acetylcysteine conjugate suppress metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in SK-Hep 1 human hepatoma cells
- in-vitro, HCC, SK-HEP-1
BioAv↝, Sinigrin, the predominant aliphatic glucosinolate in cruciferous vegetables, is hydrolyzed to yield allyl isothiocyanate (AITC), which, after absorption and metabolism in humans, is excreted in the urine as an N-acetylcysteine (NAC) conjugate.
TumCP↓, AITC and NAC-AITC suppress SK-Hep 1 cell proliferation in a dose-dependent manner; by 25% and 30% for 10 microM AITC and 10 microM NAC-AITC, respectively.
MMP2↓, significant downregulation of MMP-2/-9 expression in SK-Hep1 cells treated with 0.1-5 microM AITC and NAC-AITC compared with controls.
MMP9↓,
eff↑, NAC-AITC inhibited cancer cell adhesion and invasion much more potently than its parent compound.

9229- AITC,    Allyl isothiocyanate as a cancer chemopreventive phytochemical
- Review, Var, NA
BioAv↑, Bioavailability of AITC is extremely high, as nearly 90% of orally administered AITC is absorbed.
BioAv↑, tissue levels of AITC equivalent in the urinary bladder were 14-79 times higher than in other organs after oral AITC administration to rats.
eff↑, and cellular GSTs enhance ITC accumulation by promoting the conjugation reactions
selectivity↑, More interestingly, AITC appears to be significantly less toxic to normal cells.
MMP↓, AITC at 10 μM for 24 h rendered nearly 30% cells apoptotic, which was associated with disruption of mitochondrial transmembrane potential, activation of several caspases (caspse-3, -8, -9 and -12), and activation of c-Jun N-terminal kinase (JNK)
Casp3↑,
Casp8↑,
Casp9↑,
Casp12↑,

9235- AITC,    Anticancer Activity, Mechanism, and Delivery of Allyl Isothiocyanate
- Review, Var, NA
tumCV↓, AITC inhibited cell viability and induced apoptosis in the human cervical cancer HeLa cell line in vitro when treated with 45 μM for 72 h
Apoptosis↑,
TumCCA↑, GBM 8401 celsl:This decrease in cell viability was mediated by G2/M phase cell cycle arrest due to a decrease in CDK1, cyclin A, and cyclin B
CDK1↓,
cycA1/CCNA1↓,
CycB/CCNB1↓,
DNAdam↑, DNA fragmentation and the downregulation of p-AKT and p-mTOR. This promoted the mitochondria-dependent apoptotic pathway by augmenting caspase-3 and caspase-9 activity
p‑Akt↓,
p‑mTOR↓,
Casp3↑,
Casp9↑,
ROS↑, production of reactive oxygen species (ROS) and loss of mitochondrial membrane potential (∆Ψm), appeared in the AITC-treated MDA-MB-468 cells
MMP↓,
selectivity↑, They also reported that AITC failed to cause G2/M phase arrest or the induction of apoptosis in normal prostate epithelial cell line (PrEC) cells
TumAuto↑, AITC was reported to induce protective autophagy through BECN1 (beclin-1) upregulation in PC3 human prostate cancer cells
Beclin-1/ATG6↑,
HATs↓, decreased the activity of various HATs (acetyltransferases), HDACs (histone deacetylases), and HMTs (histone methyl transferases), t
HDAC↓,
HMTs↓,
p‑ERK↑, figure 4
P21↑,
CDC25↓,
CDK1↓,
FasL↑,
TRAIL↑,
MAPK↑,
ATF6↑,
GRP94↑,
GRP78/BiP↑,
Cal1↑,
cal2↑,
CHOP/DDIT3↑,
BAX↑,
Endoglin↑,
AIF↑,
APAF1↑,
Cyt‑c↑,
TIMP1↑,
GSTs↑,
GGT/CD224↑,
NRF2↓,
BioAv↓, the delivery of AITC has considerable challenges because of its poor solubility, instability, degradation, and offset toxicity.
BioAv↑, AITC could be a reasonable anticancer agent for the treatment of bladder cancer
Risk↓, Studies suggest that the anticancer activity is attributed mainly to ITCs (isothiocyanates) present in these plants.

9237- AITC,    Corn oil and milk enhance the absorption of orally administered allyl isothiocyanate in rats
- in-vivo, Nor, NA
*BioAv↑, when allyl isothiocyanate (2 or 4μmol) was coadministered with corn oil or milk showed a greater increase (1.4±0.22 or 2.7±0.34μmol or 1.2±0.32 or 2.5±0.36μmol, 1.6- to 1.8-fold or 1.5-fold, respectively) than when allyl isothiocyanate (2 or 4

5355- AL,    Mini-review: The health benefits and applications of allicin
- Review, Var, NA
*BioAv↑, another key property of allicin is its hydrophobicity, which allows it to be absorbed easily through the cell membrane without causing any physical or chemical damage to the phospholipid bilayer, thereby allowing its rapid metabolism to produce pharm
*cardioP↑, Allicin exhibits protective effects in multiple organ systems, including the brain, intestines, lungs, liver, kidneys, prostate, and heart.
*hepatoP↑,
*RenoP↑,
*Half-Life↝, half-life (t1/2)of allicin was 227 min–260 min. Because allicin is eliminated from the body by the respiratory tract, the concentration of allicin in lung tissue is significantly lower than that in the blood
*BioAv↓, We believe that the bioavailability of allicin is relatively low for the following reasons: At first, allicin is characterized by a distinctive garlic odor and chemical instability. It can be easily degraded under room temperature.
*neuroP↑, Neuroprotective activity
*cognitive↑, On the other hand, allicin improves cognitive deficits via Protein kinase R-like endoplasmic reticulum kinase (PERK)/Nuclear factor erythroid-2-related factor 2 (NRF2) signaling pathway and c-Jun N-terminal kinase (JNK) signaling pathways
*ROS↓, They found that allicin suppressed ROS generation and decreased lipid peroxidation in 6-hydroxydopamine (6-OHDA)-induced Pheochromocytoma 12 (PC12) cells
*lipid-P↓,
*DNArepair↑, Allicin not only directly protects DNA, but also indirectly protects DNA through antioxidant activity and regulation of oxidizing enzymes
*ChemoSen↑, Allicin combined with other chemotherapy drugs showed a better anti-cancer effect

5356- AL,    Therapeutic role of allicin in gastrointestinal cancers: mechanisms and safety aspects
- Review, GC, NA
Apoptosis↑, induction of apoptosis, inhibition of proliferation, and disruption of cancer cell signaling pathways, including the MAPK, PI3K/AKT, and NF-κB pathways.
TumCP↓,
MAPK↓,
PI3K↓,
Akt↓,
NF-kB↓,
AntiCan↑, Allicin and its other derivatives, such as diallyl disulfide (DADS) and ajoene, have been found to have strong anticancer potential both in vitro and in vivo.
ChemoSen↑, effectiveness of allicin in augmenting conventional chemotherapy and retarding tumor growth proves that allicin is one of the most efficient complementary therapies.
TumCCA↑, In liver cancer, allicin has been shown to mediate cell cycle arrest and apoptosis
Apoptosis↑,
BioAv↑, Allicin (diallyl thiosulfinate) is a compound that is generated when a garlic clove is crushed
selectivity↑, Furthermore, it has no influence on the growth of healthy intestinal cells when it causes stomach cancer cells to undergo apoptosis
TGF-β↓, Allicin can reduce the production of TGF-β2 and its receptor after directly entering gastric cancer cells.
ROS↑, It induces oxidative stress by generating reactive oxygen species (ROS), leading to DNA damage and activation of key apoptotic mediators such as phospho-p53 and p21 [81].
DNAdam↑,
p‑P53↑,
P21↑,
cycD1/CCND1↓, Additionally, cyclin D1, cyclin E, and cyclin-dependent kinases (CDKs) can all be inhibited by allicin.
cycE/CCNE↓,
CDK4↓, suppressing the CDK-4/6/cyclin D complex
CDK6↓,
MMP↓, By lowering the outer mitochondrial membrane potential (MMP), allicin raises levels of nuclear factor kappa B (NF-κB), the proapoptotic protein Bax, while decreasing the antiapoptotic protein Bcl-2, which leads to apoptosis.
NF-kB↑,
BAX↑,
Bcl-2↓,
ER Stress↑, cellular effects of allicin, including its role in inducing ER stress
Casp↑, enhancing caspase activation and apoptosis-inducing factor (AIF)-mediated cell death.
AIF↑,
Fas↑, increasing Fas receptor expression and its binding to Fas ligand (FasL), leading to apoptosis through caspase-8 and cytochrome c activation.
Casp8↑,
Cyt‑c↑,
cl‑PARP↑, leading to poly (ADP-ribose) polymerase (PARP) cleavage and DNA fragmentation.
Ca+2↑, allicin elevates intracellular free Ca2⁺ levels, causing endoplasmic reticulum (ER) stress, which plays a critical role in apoptosis induction
*NRF2↑, by activating the Nrf2 pathway via KLF9, allicin protects against arsenic trioxide-induced liver damage,
*chemoP↑, Additionally, allicin has shown promise in reducing hepatotoxicity caused by tamoxifen (TAM), a commonly used treatment for hormone-dependent breast cancer
*GutMicro↑, Shi et al. [85] found that allicin can ameliorate high-fat diet-induced obesity in mice by altering their gut microbiome.
CycB/CCNB1↑, DATS impaired cell survival in the G2 phase by significantly upregulating cyclins A2 and B1.
H2S↑, DATS can also react with the cellular thiol glutathione to create H2S gas, which can control several other cellular functions [79].
HIF-1↓, allicin treatment (40 µg/ml) for NSCLC lowers the expression of HIF-1 and HIF-2 in hypoxic cells [73]
RadioS↑, Allicin has been shown to increase the sensitivity of X-ray radiation therapy in colorectal cancer, presumably by suppressing the levels of NF-κB, IKKβ mRNA, p-NF-κB, and p-IKKβ protein expression in vitro and in vivo

1916- AL,    Allicin Bioavailability and Bioequivalence from Garlic Supplements and Garlic Foods
- Review, Nor, NA
*BioAv↝, For enteric tablets, ABB varied from 36–104%
*eff↓, but it was reduced to 22–57% when consumed with a high-protein meal, due to slower gastric emptying.
*BioAv↝, garlic powder capsules gave 26–109%
*BioAv↝, Kwai garlic powder tablets, which have been used in a large number of clinical trials, gave 80% ABB, validating it as representing raw garlic in those trials
*eff↑, Hence, many brands of garlic supplements have been enteric-coated to prevent disintegration in the stomach
*Half-Life∅, Hence, many brands of garlic supplements have been enteric-coated to prevent disintegration in the stomach
*eff↑, all brands of normal tablets gave high allicin bioavailability
*eff↑, Hence, both low-protein and high-protein meals would provide a gastric pH ≥ 4.0 for an ample amount of time for the alliinase in disintegrated normal tablets and capsules to convert most of the alliin to allicin in the stomach.
*Dose∅, Three tablets has been the most common dose used in these trials. The N1 tablets in these trials have been consistently standardized to contain 3.9 mg alliin/tablet and to yield 1.8 mg allicin/tablet
*eff↑, The bioavailability of allicin from garlic powder supplements containing alliin and active alliinase can be as high as that from an equivalent amount of crushed raw garlic containing maximum allicin, when consumed with a meal.

5165- AL,    The human allicin-proteome: S-thioallylation of proteins by the garlic defence substance allicin and its biological effects
- in-vitro, AML, Jurkat - in-vitro, Nor, L929
necrosis↑, Allicin induces apoptosis or necrosis in a dose-dependent manner but biocompatible doses influence cellular metabolism and signalling cascades.
Thiols↓, Oxidation of protein thiols and depletion of the glutathione pool are thought to be responsible for allicin's physiological effects.
GSH↓,
ENO1↓, allicin caused inhibition of enolase activity, an enzyme considered a cancer therapy target.
Zn2+↑, Allicin leads to Zn2+ release in murine EL-4 cells
Glycolysis↓, suggests that allicin can inhibit glycolysis which provides electron donors for ATP generation required for cellular biosynthesis pathways and growth of the cells.
ATP↓,
BioAv↓, achieving therapeutically relevant concentrations of allicin via the oral route is therefore unlikely and more direct routes of application to the desired site of action need to be considered

2560- AL,    Effect of garlic on platelet aggregation in humans: a study in healthy subjects and patients with coronary artery disease
- ex-vivo, Nor, NA
*AntiAg↑, Garlic and its components are known to possess antiplatelet activity
BioAv↝, Though garlic components leave the body quickly, a slow build-up of the active ingredients may take place.
Dose↝, Each capsule contained oil equivalent to I g of raw garlic. oil extract of garlic was encapsulated. 2 capsules of garlic three times a day (i.e. 6 capsules/day) for a period of 1 month.

2558- AL,    Allicin, an Antioxidant and Neuroprotective Agent, Ameliorates Cognitive Impairment
- Review, AD, NA
*AntiCan↑, Allicin has shown anticancer, antimicrobial, antioxidant properties and also serves as an efficient therapeutic agent against cardiovascular diseases
*antiOx↑,
*cardioP↑,
*neuroP↑, present review describes allicin as an antioxidant, and neuroprotective molecule
cognitive↑, that can ameliorate the cognitive abilities in case of neurodegenerative and neuropsychological disorders.
*ROS↓, As an antioxidant, allicin fights the reactive oxygen species (ROS) by downregulation of NOX (NADPH oxidizing) enzymes, it can directly interact to reduce the cellular levels of different types of ROS produced by a variety of peroxidases.
*NOX↓,
*TLR4↓, inhibition of TLR4/MyD88/NF-κB, P38 and JNK pathways.
*NF-kB↓,
*JNK↓,
*AntiAg↑, A low concentration of allicin (0.4 mM) can inhibit the platelet aggregation up to 90%, the impact is significantly higher than of similar concentration of aspirin.
*H2S↑, Allicin decomposes rapidly and undergoes a series of reactions with glutathione resulting in the production of hydrogen sulphide (H2S).
*BP↓, H2S is a gaseous signalling molecule involved in the regulation of blood pressure.
Telomerase↓, Allicin inhibits the activity of telomerase in a dose dependent manner subsequently inhibiting the proliferation in the cancer cells
*Insulin↑, Studies have shown a significant increase in the blood insulin levels after treatment with allicin
BioAv↝, optimum temperature for the activity of alliinase is 33 °C, it operates best at pH 6.5, the enzyme is sensitive to acids [42,43] (Figure 3), enteric-coated formulations of garlic supplements are therefore recommended
*GSH↑, It helps to lower the hyperglycaemic conditions and improves the glutathione and catalase biosynthesis [37,38]
*Catalase↑,

2663- AL,    Therapeutic Effect of Allicin on Glioblastoma
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG
BioAv↝, After processing, such as cutting, crushing, chewing, or dehydration, alliinase rapidly breaks down alliin to form allicin. Allicin is immediately decomposed to other organosulfur compounds such as diallyl sulphide (DAS), diallyl disulfide(DADS), and
TumCCA↑, The results show DATS can reduce tumor growth by inhibits cell cycle progression and promotes p53-mediated tumor suppression pathways
P53↑,
HDAC↓, The findings demonstrate that DATS can inhibit U87MG cell growth in vivo by inhibiting HDAC [10].
CSCs↓, Inhibition of cancer stem cells(CSC)
ROS↑, DATS can induce apoptosis by ROS through regulation of Bcl-2 and have anticancer effect on human glioblastoma (U87MG) and neuroblastoma (SH-SY5Y) cells
ChemoSen↑, The most interesting thing is allicin can enhance the sensitivity of TMZ-resistant cells to TMZ by inhibiting MGMT expression.
MGMT↓,

3443- ALA,    Molecular and Therapeutic Insights of Alpha-Lipoic Acid as a Potential Molecule for Disease Prevention
- Review, Var, NA - Review, AD, NA
*antiOx↑, antioxidant potential and free radical scavenging activity.
*ROS↓,
*IronCh↑, Lipoic acid acts as a chelating agent for metal ions, a quenching agent for reactive oxygen species, and a reducing agent for the oxidized form of glutathione and vitamins C and E.
*cognitive↑, α-Lipoic acid enantiomers and its reduced form have antioxidant, cognitive, cardiovascular, detoxifying, anti-aging, dietary supplement, anti-cancer, neuroprotective, antimicrobial, and anti-inflammatory properties.
*cardioP↓,
AntiCan↑,
*neuroP↑,
*Inflam↓, α-Lipoic acid can reduce inflammatory markers in patients with heart disease
*BioAv↓, bioavailability in its pure form is low (approximately 30%).
*AntiAge↑, As a dietary supplements α-lipoic acid has become a common ingredient in regular products like anti-aging supplements and multivitamin formulations
*Half-Life↓, it has a half-life (t1/2) of 30 min to 1 h.
*BioAv↝, It should be stored in a cool, dark, and dry environment, at 0 °C for short-term storage (few days to weeks) and at − 20 °C for long-term storage (few months to years).
other↝, Remarkably, neither α-lipoic acid nor dihydrolipoic acid can scavenge hydrogen peroxide, possibly the most abundant second messenger ROS, in the absence of enzymatic catalysis.
EGFR↓, α-Lipoic acid inhibits cell proliferation via the epidermal growth factor receptor (EGFR) and the protein kinase B (PKB), also known as the Akt signaling, and induces apoptosis in human breast cancer cells
Akt↓,
ROS↓, α-Lipoic acid tramps the ROS followed by arrest in the G1 phase of the cell cycle and activates p27 (kip1)-dependent cell cycle arrest via changing of the ratio of the apoptotic-related protein Bax/Bcl-2
TumCCA↑,
p27/CDKN1B↑,
PDH↑, α-Lipoic acid drives pyruvate dehydrogenase by downregulating aerobic glycolysis and activation of apoptosis in breast cancer cells, lactate production
Glycolysis↓,
ROS↑, HT-29 human colon cancer cells; It was concluded that α-lipoic acid induces apoptosis by a pro-oxidant mechanism triggered by an escalated uptake of mitochondrial substrates in oxidizable form
*Synergy↑, Several studies have found that combining α-lipoic acid and omega-3 fatty acids has a synergistic effect in slowing functional and cognitive decline in Alzheimer’s disease
*memory↑, α-lipoic acid inhibits brain weight loss, downregulates oxidative tissue damage resulting in neuronal cell loss, repairs memory and motor function,
*motorD↑,
*GutMicro↑, modulates the gut microbiota without reducing the microbial diversity (

3542- ALA,    Chelation: Harnessing and Enhancing Heavy Metal Detoxification—A Review
- Review, Var, NA
*antiOx↑, powerful antioxidant that regenerates other antioxidants (e.g., vitamins E and C, and reduced glutathione) and has metal-chelating activity.
*VitE↑,
*VitC↑,
*GSH↑,
*IronCh↑,
*BioAv↑, Both fat and water soluble, it is readily absorbed from the gut and crosses cellular and blood-brain membrane barriers
*BBB↑,

3546- ALA,    Cognitive and Mood Effect of Alpha-Lipoic Acid Supplementation in a Nonclinical Elder Sample: An Open-Label Pilot Study
- Study, AD, NA
*antiOx↑, (ALA), a known antioxidant compound abundant in vegetables and animal tissues, in reducing oxidative stress in the aging brain and preventing cognitive decline.
*ROS↓,
*cognitive∅, no statistically significant effects either on cognitive function, executive function, or mood were found
*lipid-P↓, ALA has been shown to reduce lipid peroxidation and increase the activity of antioxidant molecules in different areas of the brain of experimental animals
*memory↑, ALA has been suggested to improve memory by increasing the activity of choline acetyltransferase (ChAT)
*ChAT↑,
*Acetyl-CoA↑, a crucial step in the biosynthesis of acetylcholine, in the hippocampi of treated rats
*Aβ↓, ALA administration can inhibit the formation of beta-amyloid fibrils and their expansion, thus exerting a direct effect on a known mechanism involved in neurodegenerative diseases
*BioAv↑, ALA is abundantly present in vegetables and animal tissues [17], is promptly bioavailable, and has no known toxic effects on animals and human subjects
*BBB↑, ALA has been demonstrated to successfully cross the blood–brain barrier in animal models
*toxicity∅, and no collateral effects have been observed at the oral daily doses currently employed as supplements (from 50 to 2400 mg/day)

3549- ALA,    Important roles of linoleic acid and α-linolenic acid in regulating cognitive impairment and neuropsychiatric issues in metabolic-related dementia
- Review, AD, NA
*Inflam↓, LA and ALA attenuate neuroinflammation by modulating inflammatory signaling.
*other↝, ratio of LA to ALA in typical Western diets is reportedly 8–10:1 or higher, which is rather higher than the ideal ratio of LA to ALA (1–2:1) required to reach the maximal conversion of ALA to its longer chain PUFAs
*other↝, LA and ALA are essential PUFAs that must be obtained from dietary intake because they cannot be synthesized de novo
*neuroP↑, several studies have also suggested that lower dietary intake of LA influences AA metabolism in brain and subsequently causes progressive neurodegenerative disorders
*BioAv↝, LA cannot be synthesized in the human body
*adiP↑, study suggested that LA-rich oil consumption leads to the high levels of adiponectin in the blood [114], which could stimulate mitochondrial function in the liver and skeletal muscles for energy thermogenesis
*BBB↑, Although LA can penetrate the BBB, most of the LA that enters the brain cannot be changed into AA [48,49], and 59 % of the LA that enters the brain is broken down by fatty acid β-oxidation
*Casp6↓, In neurons, LA and ALA attenuate the activation of cleaved caspase-3/-9, p-NF-Kb and the production of TNF-a, IL-6, IL-1b, and ROS by binding GPR40 and GPR120.
*Casp9↓,
*TNF-α↓,
*IL6↓,
*IL1β↓,
*ROS↓,
*NO↓, LA reduces NO production and inducible nitric oxide synthases (iNOS) protein expression in BV-2 microglia
*iNOS↓,
*COX2/PTGS2↓, ALA increases antioxidant enzyme activities in the brain [182] and inhibits the activation of COX-2 in AD models
*JNK↓, ALA has also been shown to suppress the activation of c-Jun N-terminal kinases (JNKs) and p-NF-kB p65 (Ser536), which is involved in inflammatory signaling
*p‑NF-kB↓,
*Aβ↓, and to inhibit Aβ aggregation and neuronal cell necrosis
*BP↓, LA also improves blood pressure, blood triglyceride and cholesterol levels, and vascular inflammation
*memory↑, One study suggested that long-term intake of ALA enhances memory function by increasing hippocampal neuronal function through activation of cAMP response element-binding protein (CREB) [192], extracellular signal-regulated kinase (ERK), and Akt signa
*cAMP↑,
*ERK↑,
*Akt↑,
cognitive?, Furthermore, ALA administration inhibits Aβ induced neuroinflammation in the cortex and hippocampus and enhances cognitive function

3550- ALA,    Mitochondrial Dysfunction and Alpha-Lipoic Acid: Beneficial or Harmful in Alzheimer's Disease?
- Review, AD, NA
*antiOx↑, antioxidant and anti-inflammatory properties
*Inflam↓,
*PGE2↓, α-LA has mechanisms of epigenetic regulation in genes related to the expression of various inflammatory mediators, such PGE2, COX-2, iNOS, TNF-α, IL-1β, and IL-6
*COX2/PTGS2↓,
*iNOS↓,
*TNF-α↓,
*IL1β↓,
*IL6↓,
*BioAv↓, α-LA has rapid uptake and low bioavailability and the metabolism is primarily hepatic
*Ach↑, α-LA increases the production of acetylcholine [30], inhibits the production of free radicals [31], and promotes the downregulation of inflammatory processes
*ROS↓,
*cognitive↑, Studies have shown that patients with mild AD who were treated with α-LA showed a slower progression of cognitive impairment
*neuroP↑, α-LA is classified as an ideal neuroprotective antioxidant because of its ability to cross the blood-brain barrier and its uniform uptake profile throughout the central and peripheral nervous systems
*BBB↑,
*Half-Life↓, α-LA presented a mean time to reach the maximum plasma concentration (tmax) of 15 minutes and a mean plasma half-life (t1/2) of 14 minutes
*BioAv↑, LA consumption is recommended 30 minutes before or 2 hours after food intake
*Casp3↓, α-LA had an effect on caspases-3 and -9, reducing the activity of these apoptosis-promoting molecules to basal levels
*Casp9↓,
*ChAT↑, α-LA increased the expression of M2 muscarinic receptors in the hippocampus and M1 and M2 in the amygdala, in addition to ChaT expression in both regions.
*cognitive↑, α-LA acts on these apoptotic signalling pathways, leading to improved cognitive function and attenuation of neurodegeneration.
*eff↑, Based on their results, the authors suggest that treatment with α-LA would be a successful neuroprotective option in AD, at least as an adjuvant to standard treatment with acetylcholinesterase inhibitors.
*cAMP↑, The increase of cAMP caused by α-LA inhibits the release of proinflammatory cytokines, such as IL-2, IFN-γ, and TNF-α.
*IL2↓,
*INF-γ↓,
*TNF-α↓,
*SIRT1↑, Protein expression encoded by SIRT1 showed higher levels after α-LA treatment, especially in liver cells.
*SOD↑, antioxidant enzymes (SOD and GSH-Px) and malondialdehyde (MDA) were analysed by ELISA after 24 h of MCAO, which showed that the enzymatic activities were recovered and MDA was reduced in the α-LA-treated groups i
*GPx↑,
*MDA↓,
*NRF2↑, The ratio of nucleus/cytoplasmic Nrf2 was higher in the α-LA group 40 mg/kg, indicating that the activation of this factor also occurred in a dose-dependent manner

3551- ALA,    Alpha lipoic acid treatment in late middle age improves cognitive function: Proteomic analysis of the protective mechanisms in the hippocampus
- in-vivo, AD, NA
*cognitive↑, ALA improves cognitive function in ageing mice.
*Apoptosis↓, ALA downregulates apoptosis, and neuroinflammatory associated proteins in ageing mice.
*Inflam↓,
*antiOx↑, Alpha lipoic acid (ALA), a powerful antioxidant, has the potential to relieve age-related cognitive impairment and neurodegenerative disease.
*BioAv↝, Alpha lipoic acid (ALA) is a sulfur-containing and both water-soluble and lipid-soluble coenzyme involved in the energy metabolism of carbohydrates, proteins and lipids
*neuroP↑, neuroprotective action of alpha lipoic acid has been demonstrated in a number of cellular or animal models of Parkinson's disease (PD), AD and amyotrophic lateral sclerosis (ALS) due to its antioxidative and anti-inflammatory properties

3545- ALA,    Potential therapeutic effects of alpha lipoic acid in memory disorders
- Review, AD, NA
*neuroP↑, potential therapeutic effects for the prevention or treatment of neurodegenerative disease
*Inflam↓, ALA is able to regulate inflammatory cell infiltration into the central nervous system and to down-regulate VCAM-1 and human monocyte adhesion to epithelial cells
*VCAM-1↓, down-regulate vascular cell adhesion molecule-1 (VCAM-1) and the human monocyte adhesion to epithelial cells
*5HT↑, ALA is able to improve the function of the dopamine, serotonin and norepinephrine neurotransmitters
*memory↑, scientific evidence shows that ALA possesses the ability to improve memory capacity in a number of experimental neurodegenerative disease models and in age-related cognitive decline in rodents
*BioAv↝, Between 27 and 34% of the oral intake is available for tissue absorption; the liver is one of the main clearance organs on account of its high absorption and storage capacity
*Half-Life↓, The plasma half-life of ALA is approximately 30 minutes. Peak urinary excretion occurs 3-6 hours after intake.
*NF-kB↓, As an inhibitor of NF-κβ, ALA has been studied in cytokine-mediated inflammation
*antiOx↑, In addition to the direct antioxidant properties of ALA, some studies have shown that both ALA and DHLA and a great capacity to chelate redox-active metals, such as copper, free iron, zinc and magnesium, albeit in different ways (
*IronCh↑, ALA is able to chelate transition metal ions and, therefore, modulate the iron- and copper-mediated oxidative stress in Alzheimer’s plaques
*ROS↓, iron and copper chelation with DHLA may explain the low level of free radical damage in the brain and the improvement in the pathobiology of Alzheimer’s Disease
*ATP↑, ALA may increase the mitochondrial synthesis of ATP in the brain of elderly rats, thereby increasing the activity of the mitochondrial enzymes
*ChAT↑, ALA may also play a role in the activation of the choline acetyltransferase enzyme (ChAT), which is essential in the anabolism of acetylcholine
*Ach↑,
*cognitive↑, One experimental study has shown that in rats that had been administered ALA there was an inversion in the cognitive dysfunction with an increase in ChAT activity in the hippocampus
*lipid-P↓, administration of ALA reduces lipid peroxidation in different areas of the brain and increases the activity of antioxidants such as ascorbate (vitamin C), α-tocopherol (vitamin E), glutathione,
*VitC↑,
*VitE↑,
*GSH↑,
*SOD↑, and also the activity of superoxide dismutase, catalase, glutathione-peroxidase, glutathione-reductase, glucose-6-P-dehydrogenase
*Catalase↑,
*GPx↑,
*Aβ↓, Both ALA and DHLA have been seen to inhibit the formation of Aβ fibrils

3539- ALA,    Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential
- Review, AD, NA
*ROS↓, scavenges free radicals, chelates metals, and restores intracellular glutathione levels which otherwise decline with age.
*IronCh↑, LA preferentially binds to Cu2+, Zn2+ and Pb2+, but cannot chelate Fe3+, while DHLA forms complexes with Cu2+, Zn2+, Pb2+, Hg2+ and Fe3+
*GSH↑,
*antiOx↑, LA has long been touted as an antioxidant
*NRF2↑, activate Phase II detoxification via the transcription factor Nrf2
*MMP9↓, lower expression of MMP-9 and VCAM-1 through repression of NF-kappa-B.
*VCAM-1↓,
*NF-kB↓,
*cognitive↑, it has been used to improve age-associated cardiovascular, cognitive, and neuromuscular deficits, and has been implicated as a modulator of various inflammatory signaling pathways
*Inflam↓,
*BioAv↝, LA bioavailability may be dependent on multiple carrier proteins.
*BioAv↝, observed that approximately 20-40% was absorbed [
*BBB↑, LA has been shown to cross the blood-brain barrier in a limited number of studies
*H2O2∅, Neither species is active against hydrogen peroxide
*neuroP↑, chelation of iron and copper in the brain had a positive effect in the pathobiology of Alzheimer’s Disease by lowering free radical damage
*PKCδ↑, In addition to PKCδ, LA activates Erk1/2 [92, 93], p38 MAPK [94], PI3 kinase [94], and Akt [94-97].
*ERK↑,
*MAPK↑,
*PI3K↑,
*Akt↑,
*PTEN↓, LA decreases the activities of Protein Tyrosine Phosphatase 1B [99], Protein Phosphatase 2A [95], and the phosphatase and tensin homolog PTEN
*AMPK↑, LA activates peripheral AMPK
*GLUT4↑, In skeletal muscle, LA is proposed to recruit GLUT4 from its storage site in the Golgi to the sarcolemma, so that glucose uptake is stimulated by the local increase in transporter abundance.
*GlucoseCon↑,
*BP↝, Feeding LA to hypertensive rats normalized systolic blood pressure and cytosolic free Ca2+
*Synergy↑, Clinically, LA administration (in combination with acetyl-L-carnitine) showed some promise as an antihypertensive therapy by decreasing systolic pressure in high blood pressure patients and subjects with the metabolic syndrome
*ICAM-1↓, decreased demyelination and spinal cord expression of adhesion molecules (ICAM-1 and VCAM-1)
*VCAM-1↓,
*Dose↝, Considering the transient cellular accumulation of LA following an oral dose, which does not exceed low micromolar levels, it is entirely possible that some of the cellular effects of LA when given at supraphysiological concentrations may be not be c

278- ALA,    The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment
- Review, Var, NA
ROS↑, direct anticancer effect of the antioxidant ALA is manifested as an increase in intracellular ROS levels in cancer cells
NRF2↑, enhance the activity of the anti-inflammatory protein nuclear factor erythroid 2–related factor 2 (Nrf2), thereby reducing tissue damage
Inflam↓,
frataxin↑,
*BioAv↓, Oral ALA has a bioavailability of approximately 30% due to issues such as poor stability in the stomach, low solubility, and hepatic degradation.
ChemoSen↑, ALA can enhance the functionality of various other anticancer drugs, including 5-fluorouracil in colon cancer cells and cisplatin in MCF-7 breast cancer cells
Hif1a↓, it is inferred that lipoic acid may inhibit the expression of HIF-1α
Synergy↑, act as a synergistic agent with natural polyphenolic substances such as apigenin and genistein
FAK↓, ALA inhibits FAK activation by downregulating β1-integrin expression and reduces the levels of MMP-9 and MMP-2
ITGB1↓,
MMP2↓,
MMP9↓,
EMT↓, ALA inhibits the expression of EMT markers, including Snail, vimentin, and Zeb1
Snail↓,
Vim↓,
Zeb1↓,
P53↑, ALA also stimulates the mutant p53 protein and depletes MGMT
MGMT↓, depletes MGMT by inhibiting NF-κB signalling, thereby inducing apoptosis
Mcl-1↓,
Bcl-xL↓,
Bcl-2↓,
survivin↓,
Casp3↑,
Casp9↑,
BAX↑,
p‑Akt↓, ALA inhibits the activation of tumour stem cells by reducing Akt phosphorylation.
GSK‐3β↓, phosphorylation and inactivation of GSK3β
*antiOx↑, indirect antioxidant protection through metal chelation (ALA primarily binds Cu2+ and Zn2+, while DHLA can bind Cu2+, Zn2+, Pb2+, Hg2+, and Fe3+) and the regeneration of certain endogenous antioxidants, such as vitamin E, vitamin C, and glutathione
*ROS↓, ALA can directly quench various reactive species, including ROS, reactive nitrogen species, hydroxyl radicals (HO•), hypochlorous acid (HclO), and singlet oxygen (1O2);
selectivity↑, In normal cells, ALA acts as an antioxidant by clearing ROS. However, in cancer cells, it can exert pro-oxidative effects, inducing pathways that restrict cancer progression.
angioG↓, Combining these two hypotheses, it can be hypothesized that ALA may regulate copper and HIF-2α to limit tumor angiogenesis.
MMPs↓, ALA was shown to inhibit invasion by decreasing the mRNA levels of key matrix metalloproteinases (MMPs), specifically MMP2 and MMP9, which are crucial for the metastatic process
NF-kB↓, ALA has been shown to enhance the efficacy of the chemotherapeutic drug paclitaxel in breast and lung cancer cells by inhibiting the NF-κB signalling pathway and the functions of integrin β1/β3 [138,139]
ITGB3↓,
NADPH↓, ALA has been shown to inhibit NADPH oxidase, a key enzyme closely associated with NP, including NOX4

297- ALA,    Insights on the Use of α-Lipoic Acid for Therapeutic Purposes
- Review, BC, SkBr3 - Review, neuroblastoma, SK-N-SH - Review, AD, NA
PDH↑, ALA is capable of activating pyruvate dehydrogenase in tumor cells.
TumCG↓, ALA also significantly inhibited tumor growth in mouse xenograft model using BCPAP and FTC-133 cells
ROS↑, ALA is able to generate ROS, which promote ALA-dependent cell death in lung cancer [75], breast cancer [76] and colon cancer
AMPK↑,
EGR4↓,
Half-Life↓, Data suggests that ALA has a short half-life and bioavailability (about 30%)
BioAv↝,
*GSH↑, Moreover, it is able to increase the glutathione levels inside the cells, that chelate and excrete a wide variety of toxins, especially toxic metals from the body
*IronCh↑, The existence of thiol groups in ALA is responsible for its metal chelating abilities [14,35].
*ROS↓, ALA exerts a direct impact in oxidative stress reduction
*antiOx↑, ALA is being referred as the universal antioxidant
*neuroP↑, ALA has neuroprotective effects on Aβ-mediated cytotoxicity
*Ach↑, ALA show anti-dementia or anti-AD properties by increasing acetylcholine (ACh) production through activation of choline acetyltransferase, which increases glucose absorption
*lipid-P↓, ALA has multiple and complex effects in this way, namely scavenging ROS, transition metal ions, increasing the levels of reduced glutathione [59,63], scavenging of lipid peroxidation products
*IL1β↓, ALA downregulated the levels of the inflammatory cytokines IL-1B and IL-6 in SK-N-BE human neuroblastoma cells
*IL6↓,
TumCP↓, ALA inhibited cell proliferation, [18F]-FDG uptake and lactate formation and increased apoptosis in neuroblastoma cell lines Kelly, SK-N-SH, Neuro-2a and in the breast cancer cell line SkBr3.
FDG↓,
Apoptosis↑,
AMPK↑, ALA suppressed thyroid cancer cell proliferation and growth through activation of AMPK and subsequent down-regulation of mTOR-S6 signaling pathway in BCPAP, HTH-83, CAL-62 and FTC-133 cells lines.
mTOR↓,
EGFR↓, ALA inhibited cell proliferation through Grb2-mediated EGFR down-regulation
TumCI↓, ALA inhibited metastatic breast cancer cells migration and invasion, partly through ERK1/2 and AKT signaling
TumCMig↓,
*memory↑, Alzheimer’s Disease: ALA led to a marked improvement in learning and memory retention
*BioAv↑, Since ALA is poorly soluble, lecithin has been used as an amphiphilic matrix to enhance its bioavailability.
*BioAv↝, ALA were found to be considerably higher in adults with mean age greater than 75 years as compared to young adults between the ages of 18 and 45 years.
*other↓, ALA treatment has been recently studied by some clinical trials to explain its efficacy in preventing miscarriage
*other↝, 1800 mg of ALA or placebo were administrated orally every day, except during the period 2 days before to 4 days after administration of each dose of platinum to avoid potential interference with platinum’s antitumor effects
*Half-Life↓, Data shows a short half-life and bioavailability of about 30% of ALA due to mechanisms involving hepatic degradation, reduced ALA solubility as well as instability in the stomach.
*BioAv↑, ALA bioavailability is greatly reduced after food intake and it has been recommended that ALA should be admitted at least 2 h after eating or if taken before; meal should be taken at least 30 min after ALA administration
*ChAT↑, ALA show anti-dementia or anti-AD properties by increasing acetylcholine (ACh) production through activation of choline acetyltransferase, which increases glucose absorption
*GlucoseCon↑,

4132- Alum,    Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study
- Study, AD, NA
*Risk↑, These findings support the hypothesis that aluminum in drinking water is a risk factor for AD. This result was confirmed for AD (adjusted relative risk=2.20, 95 percent CI 1.24–3.89)
*cognitive↓,
*BioAv↑, As suggested by Taylor,30 it is plausible that there is an increase in aluminum absorption with age, so the effect of aluminum may be larger after 75 years than before.

6401- ANE,    Anethole and Its Role in Chronic Diseases
- Review, Var, NA - Review, PSA, NA
*BioAv↝, Pure anethole is a colorless to faintly yellow liquid at above 23 °C [10]. It is poorly soluble in water, is highly soluble in alcohol, and is miscible with ether and chloroform.
*other↝, Trans-anethole has a sweet herbaceous smooth odor profile [7] and a sweet taste, being more than 10 times sweeter than common sugar
CompStab↓, Ultraviolet (UV) light and visible (VIS) light, temperature, atmospheric oxygen, the prolonged storage significantly influence the chemical stability of anethole.
TNF-α↓, Figure 3
IL10↑,
CXCR4↓,
MMP2↓,
MMP9↓,
TIMP1↑,
NF-kB↓,
AP-1↓,
STAT↓,
JNK↓,
ERK↓,
MAPK↓,
PI3K↓,
Akt↓,
JAK↓,
*AntiDiabetic↓,
*neuroP↑, Anethole dithiolethione (Fig. 4), a synthetic analogue of anethole, has an attractive potential in the development of neuroprotective agents in Parkinson’s disease due to its multifaceted antioxidant activity coupled with inhibition of monoamine oxid
*Imm↑, immunomodulatory profile of anethole may offer promising alternative therapy to counteract the effects of cytotoxic chemotherapeutic agents
chemoP↑,
*AntiThr↑, Anethole as well as fennel essential oil exhibit antithrombotic properties which are linked to a broad spectrum antiplatelet activity,
*AntiAg↑,
*antiOx↑, anticataract activity through the inhibition of lens aldose reductase (IC 50 = 3.8 lg/mL) and antioxidant activity. It increases SOD and catalase activities and restores GSH levels in the sugar induced lens opacification
*SOD↑,
*GSH↑,
*Wound Healing↑, administration of pharmaceutical formulation with 20 % anethole twice daily for 15 days accelerates wound closure of injured tissue
chemoPv↑, Cancer chemoprevention activity of anethole dithiolethione may be related to the increase of intracellular glutathione, up-regulation of phase II detoxification enzymes such as glutathione-S-transferase, and inhibition of NF-kB signaling activation
*GSTs↑,
*NF-kB↓,

1152- Api,    Does Oral Apigenin Have Real Potential for a Therapeutic Effect in the Context of Human Gastrointestinal and Other Cancers?
- Analysis, Nor, NA
*BioAv↓, We find that oral intake of dietary materials would require heroic ingestion amounts and is not feasible. However, use of supplements of semi-purified apigenin in capsule form could reach target blood levels using amounts that are within the range cu
Half-Life∅, elimination half-life (T1/2) averaging 2.52 ± 0.56h
*BioAv↓, bioavailability is in the region of 30%
Dose∅, Blood and urine samples were taken following a meal consisting of 2g parsley/kg body weight–which was equivalent to ∼17mg of apigenin -> 28–337nmol/L at 6–10h after consumption
Synergy↑, Apigenin and quercetin enhance their own and each other’s bioavailability by downregulating the activity of ABC transporters
CYP1A2↓, status of apigenin as an inhibitor of CYP1A2, CYP2C9 and CYP3A4
CYP2C9↓,
CYP3A4↓,

1557- Api,    Preparation of apigenin nanocrystals using supercritical antisolvent process for dissolution and bioavailability enhancement
- in-vitro, Nor, NA
*BioAv↑, AP nanocrystals exhibited a significantly decreased tmax, a 3.6-fold higher peak plasma concentration (Cmax) and 3.4-fold higher area under the curve (AUC).

1556- Api,    Dissolution and antioxidant potential of apigenin self nanoemulsifying drug delivery system (SNEDDS) for oral delivery
- Analysis, Nor, NA
*BioAv↑, apigenin was developed as SNEDDS to solve its dissolution problem and enhance oral bioavailability
*Dose∅, Smix ratio of 1:1 and concentrations of Gelucire 44/14, Tween 80, and PEG 400 in the ranges of 5–40% w/w, 30–47.5% w/w, and 30–47.5% w/w, respectively, as shown in Table 1.

1554- Api,    A Review on Flavonoid Apigenin: Dietary Intake, ADME, Antimicrobial Effects, and Interactions with Human Gut Microbiota
- Review, Nor, NA
*BioAv↑, apigenin-7-O-glucoside, and acylated derivatives are more water soluble than apigenin [10] and their structures have a major impact on their absorption and bioavailability, with the best bioavailability occurring when apigenin is bound to β-glycosid
*BioAv↑, organic solvents like DMSO [34] and Tween 80 [31] are used to dissolve apigenin prior to their addition to an aqueous solution to increase solubility
*BioAv↑, dietary apigenin is available for metabolism by the gut microbiota
*BioAv↓, Human gut microbiota has been found to harbor enzymes that could degrade apigenin
*eff↑, This study strongly supports that the gut microbiota plays a major role in the metabolism of dietary apigenin.


Showing Research Papers: 1 to 50 of 892
Page 1 of 18 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 892

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↑, 6,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 4,   antiOx↑, 17,   ARE↓, 1,   ARE↑, 1,   Catalase↓, 7,   Catalase↑, 6,   Fenton↑, 4,   frataxin↑, 1,   GPx↓, 3,   GPx↑, 5,   GPx4↓, 11,   GPx4↑, 1,   GSH↓, 34,   GSH↑, 7,   GSH/GSSG↓, 1,   GSR↓, 2,   GSR↑, 1,   ox-GSSG↑, 1,   GSTs↓, 1,   GSTs↑, 3,   H2O2↓, 1,   H2O2↑, 4,   e-H2O2↓, 1,   i-H2O2∅, 1,   HO-1↓, 6,   HO-1↑, 12,   HO-2↓, 1,   Iron↑, 5,   Iron↝, 1,   i-Iron↑, 1,   c-Iron↑, 1,   Keap1↓, 1,   Keap1↑, 1,   lipid-P?, 1,   lipid-P↓, 8,   lipid-P↑, 16,   MDA↓, 4,   MDA↑, 5,   NADH↓, 1,   NOX↓, 1,   NOX4↓, 1,   NOX4↑, 1,   NQO1↓, 1,   NQO1↑, 6,   NRF2↓, 17,   NRF2↑, 28,   Prx↓, 1,   Prx4↑, 1,   Prx6↑, 1,   ox-PrxI↑, 1,   PrxII↓, 1,   PYCR1↓, 1,   ROS?, 1,   ROS↓, 31,   ROS↑, 244,   ROS⇅, 10,   ROS↝, 3,   i-ROS↓, 1,   i-ROS↑, 2,   mt-ROS↑, 1,   SOD↓, 10,   SOD↑, 8,   SOD1↓, 2,   SOD2↓, 4,   SOD2↑, 1,   Thiols↓, 2,   Trx↓, 2,   Trx↑, 1,   Trx1↑, 1,   TrxR↓, 8,   TrxR↑, 1,   VitC↓, 1,   VitE↓, 1,   xCT/SLC7A11↓, 2,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↓, 1,   IronCh↑, 5,   Tf↓, 1,   Tf↑, 1,   TfR1/CD71↑, 2,   Zn2+↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ADP:ATP↑, 2,   BCR-ABL↓, 1,   CDC2↓, 4,   CDC25↓, 7,   compI↓, 7,   compII↓, 1,   compIII↓, 3,   compIV↓, 1,   compV↓, 1,   EGF↓, 2,   ETC↓, 4,   ETC↑, 1,   MFN2↑, 1,   mitResp↓, 2,   Mortalin↓, 1,   mtDam↓, 1,   mtDam↑, 19,   OCR↓, 3,   OCR↑, 3,   OXPHOS↓, 6,   OXPHOS↑, 3,   mt-OXPHOS↓, 2,   PDH↓, 1,   PDH↑, 2,   PGC-1α↑, 1,   PINK1↑, 1,   SDH↓, 1,   SDH↑, 1,   SIRT3↓, 1,   SIRT3↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX?, 1,   12LOX↓, 1,   5LO↓, 5,   ACC-α↓, 1,   ACC1↓, 1,   ACLY↓, 3,   ACSL4↑, 1,   ALAT↓, 6,   ALAT↑, 1,   ALDOA↓, 1,   AMPK↑, 19,   AMPK↝, 1,   p‑AMT/GCST/T-protein↑, 1,   ATP↓, 18,   ATP↑, 1,   mt-ATP↓, 1,   CAIX/CA9↓, 2,   CAIX/CA9↑, 1,   CRM↝, 1,   ECAR↓, 3,   ECAR↝, 1,   ENO1↓, 2,   FASN↓, 6,   FDG↓, 1,   GAPDH↓, 2,   GLO-I↓, 1,   glucoNG↓, 1,   glucose↓, 1,   GlucoseCon↓, 12,   GlutaM↓, 1,   GlutMet↓, 1,   Glycolysis↓, 37,   Glycolysis↝, 1,   GSK‐3β↓, 15,   GSK‐3β↑, 5,   p‑GSK‐3β↓, 1,   H2S↑, 1,   HK1↓, 1,   HK2↓, 19,   HMG-CoA↓, 1,   IDH1↓, 1,   lactateProd↓, 14,   lactateProd↑, 1,   LDHA↓, 3,   LDL↓, 4,   lipoGen↓, 1,   MCT4↓, 2,   NADH:NAD↓, 1,   NADPH↓, 4,   PDK1 / PDPK1?, 2,   PDK1 / PDPK1↓, 9,   PDK3↑, 1,   PFK1↓, 1,   PKM2↓, 11,   SCD1↓, 1,   SIRT1↓, 8,   SIRT1↑, 8,   SIRT2↓, 1,   SIRT2↑, 1,   SREBP1/SREBF1↓, 2,   TCA↓, 3,   TCA↑, 1,   TCA↝, 1,   UGDH↓, 2,   Warburg↓, 11,  

Cell Death(tgid=5) ⓘ

AIF↑, 15,   APAF1↑, 5,   Apoptosis?, 1,   Apoptosis↓, 2,   Apoptosis↑, 199,   mt-Apoptosis↑, 2,   ASC↓, 1,   BAD↓, 2,   BAD↑, 4,   Bak↓, 1,   Bak↑, 6,   BAX↓, 3,   BAX↑, 88,   Bax:Bcl2↓, 1,   Bax:Bcl2↑, 20,   Bcl-2↓, 90,   Bcl-2↑, 4,   Bcl-xL↓, 21,   BID↓, 1,   BID↑, 3,   p‑BID↓, 1,   BIM↓, 1,   BIM↑, 5,   BNIP3↑, 1,   BNIP3↝, 1,   BOK↑, 1,   Casp↑, 41,   cl‑Casp↑, 1,   Casp1↓, 1,   Casp1↑, 3,   Casp12?, 1,   Casp12↑, 2,   cl‑Casp12↑, 1,   Casp3↓, 2,   Casp3↑, 107,   Casp3↝, 1,   cl‑Casp3↑, 14,   cl‑Casp3⇅, 1,   proCasp3↑, 1,   Casp6↑, 1,   Casp7↑, 15,   cl‑Casp7↑, 2,   Casp8↑, 26,   cl‑Casp8↑, 2,   proCasp8↑, 1,   pro‑Casp8↑, 1,   Casp9↓, 1,   Casp9↑, 67,   cl‑Casp9↑, 6,   proCasp9↓, 1,   CellShr↑, 1,   cFLIP↓, 3,   Cyt‑c↓, 3,   Cyt‑c↑, 63,   Cyt‑c↝, 1,   Diablo↑, 3,   DR5↑, 19,   Endon↑, 1,   FADD↑, 6,   Fas↑, 11,   FasL↓, 1,   FasL↑, 7,   Ferroptosis↑, 20,   GranB/GZMB↓, 1,   GranB/GZMB↝, 1,   GSDME↑, 1,   IAP1↓, 4,   IAP2/BIRC3↓, 2,   IAP2/BIRC3↑, 1,   ICD↑, 1,   iNOS↓, 16,   Mcl-1↓, 18,   Mcl-1↑, 1,   p‑Mcl-1↓, 1,   MDM2↓, 8,   MDM2↑, 2,   p‑MDM2↓, 1,   MOMP↓, 1,   MOMP↑, 6,   NAIP↓, 1,   Necroptosis↑, 2,   necrosis↑, 4,   NOXA↑, 4,   p38↓, 3,   p38↑, 14,   p‑p38↓, 1,   p‑p38↑, 2,   Paraptosis↑, 1,   Perforin↝, 1,   pS2/TFF1↓, 1,   PUMA↓, 1,   PUMA↑, 5,   Pyro↑, 3,   RIP3↑, 1,   survivin↓, 38,   TNFR 1↑, 1,   TRAIL↑, 3,   TRAIL⇅, 1,   TRAILR↑, 1,   TumCD↓, 2,   TumCD↑, 18,   XIAP↓, 21,   XIAP↑, 1,   YAP/TEAD↓, 5,  

Kinase & Signal Transduction(tgid=6) ⓘ

ABL1↓, 2,   Akt↓, 132,   Akt↑, 6,   p‑Akt↓, 33,   AKT1↓, 4,   Akt2↓, 1,   AMPKα↑, 1,   BRAF↓, 1,   CaMKII ↓, 1,   CIP2A↓, 1,   CK2↓, 2,   cMET↓, 3,   cSrc↓, 2,   DDIT4↑, 1,   DYRK1B↓, 1,   EF-1α↓, 1,   EGFR↓, 31,   EGFR↑, 2,   p‑EGFR↓, 1,   ERK↓, 43,   ERK↑, 5,   p‑ERK↓, 12,   p‑ERK↑, 1,   FGFR1↓, 3,   FGFR2↓, 1,   FOXD3↑, 1,   GNAI1↓, 1,   HER2/EBBR2↓, 8,   HGF/c-Met↓, 3,   Hippo↑, 1,   IGF-1R↓, 3,   IGF-2R↑, 1,   IKKα↓, 3,   p‑IKKα↓, 1,   IκB↓, 1,   IκB↑, 1,   JAK↓, 5,   JAK1↓, 3,   JAK1↑, 1,   JAK2↓, 10,   p‑JAK2↓, 1,   JNK↓, 6,   JNK↑, 17,   p‑JNK↑, 2,   LIMK1↓, 1,   p‑MAP2K1/MEK1↓, 1,   MAPK↓, 32,   MAPK↑, 14,   MAPK↝, 2,   p‑MAPK↓, 1,   MARK4↓, 2,   MEK↓, 3,   mTOR↓, 75,   mTOR⇅, 1,   mTOR↝, 2,   p‑mTOR↓, 7,   p‑p70S6↓, 1,   P70S6K↓, 2,   p‑P70S6K↓, 1,   p‑PDGFR-BB↓, 1,   PI3K↓, 103,   PI3K↑, 3,   PI3K↝, 1,   p‑PI3K↓, 4,   p‑PI3K↑, 1,   PKA↓, 2,   PKCδ↓, 7,   PP2A↑, 1,   PTEN↓, 3,   PTEN↑, 34,   Raf↓, 3,   c-Raf↓, 1,   RAS↓, 11,   RET↓, 1,   RIP1↑, 1,   SHP1↑, 1,   Sp1/3/4↓, 6,   Sp1/3/4↑, 1,   Src↓, 3,   p‑Src↓, 1,   STAT↓, 3,   STAT3↓, 69,   STAT3↑, 3,   p‑STAT3↓, 10,   p‑STAT3↑, 2,   STAT6↓, 3,   p‑STAT6↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF3↓, 1,   ATF4↑, 6,   ATF4↝, 1,   CBP↓, 2,   cJun↓, 3,   cJun↑, 1,   p‑cJun↑, 1,   cMyc↓, 35,   cMyc↑, 1,   p‑cMyc↑, 1,   DNMT1↓, 8,   DNMT3A↓, 2,   DNMT3B↓, 1,   DNMTs↓, 8,   EZH2↓, 5,   FOXM1↓, 4,   FOXO1↓, 3,   FOXO1↑, 2,   FOXO3↓, 2,   FOXO3↑, 4,   FOXO3↝, 1,   FOXO4↑, 2,   H3↓, 2,   H3↑, 2,   ac‑H3↑, 2,   H4↓, 1,   H4↑, 2,   ac‑H4↑, 1,   HATs↓, 5,   HATs↑, 4,   HDAC↓, 32,   HDAC1↓, 8,   HDAC10↓, 1,   HDAC2↓, 7,   HDAC3↓, 6,   HDAC4↓, 1,   HDAC6↓, 1,   HDAC8↓, 2,   HES1↓, 1,   HMTs↓, 1,   KLF4↓, 1,   miR-106b↓, 2,   miR-107↑, 1,   miR-124-3p↓, 1,   miR-139-5p↑, 1,   miR-140↑, 1,   miR-155↓, 2,   miR-19b↓, 2,   miR-200b↑, 1,   miR-200c↑, 1,   miR-203↑, 1,   miR-21↓, 8,   miR-218↑, 1,   miR-224↓, 1,   miR-25-5p↓, 1,   miR-27a-3p↓, 1,   miR-29b↓, 2,   miR-30a-5p↑, 1,   miR-339-5p↝, 1,   miR-340↓, 1,   miR-34a↓, 2,   miR-34a↑, 6,   miR-375↑, 1,   miR-384↑, 1,   miR-422a↑, 1,   miR-590-3p↑, 1,   MTA2↓, 1,   Myc↓, 5,   MYCN↓, 1,   OCT4↓, 11,   other↓, 2,   other↑, 8,   other↝, 41,   other∅, 1,   PhotoS↑, 3,   SD↑, 1,   sonoS↑, 1,   SOX2↓, 7,   SOX4↓, 2,   SOX4↑, 1,   SOX9?, 1,   tumCV?, 1,   tumCV↓, 26,   ZBTB10↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 2,   CHOP/DDIT3↓, 1,   CHOP/DDIT3↑, 16,   cl‑CHOP/DDIT3↑, 1,   CUL1↝, 1,   CUL5↝, 1,   eIF2α↓, 1,   eIF2α↑, 4,   p‑eIF2α↑, 2,   ER Stress↓, 1,   ER Stress↑, 34,   GRP78/BiP?, 1,   GRP78/BiP↓, 2,   GRP78/BiP↑, 7,   GRP78/BiP↝, 1,   GRP94↑, 1,   HSP27↝, 1,   HSP70/HSPA5↓, 2,   HSP70/HSPA5↑, 1,   HSP70/HSPA5↝, 1,   HSP90↓, 12,   PERK↑, 8,   Proteasome↓, 1,   UPR↑, 6,   XBP-1↓, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 2,   ATG7↑, 2,   Beclin-1/ATG6↓, 1,   Beclin-1/ATG6↑, 10,   CTSK↓, 1,   LAMP1?, 1,   LC3‑Ⅱ/LC3‑Ⅰ↓, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3B-II↑, 2,   LC3II↓, 2,   LC3II↑, 14,   p62↓, 5,   p62↑, 3,   PARK2↑, 1,   SESN2↑, 2,   TFEB↑, 1,   TumAuto↓, 2,   TumAuto↑, 42,   TumAuto⇅, 1,   TumAuto↝, 2,  

DNA Damage & Repair(tgid=10) ⓘ

8-oxo-dG↓, 1,   APE1/APEX1↓, 1,   ATM?, 1,   ATM↑, 2,   BRCA1↓, 2,   p‑BRCA1↑, 1,   DFF45↓, 1,   DNAdam↓, 3,   DNAdam↑, 55,   DNAdam⇅, 1,   DNAdamC↑, 1,   DNArepair↓, 3,   DNArepair↑, 1,   ERCC3↑, 1,   m-FAM72A↓, 1,   G9a↓, 1,   hTERT/TERT↓, 14,   MGMT↓, 2,   NKX3.1↓, 1,   p16↑, 2,   P53?, 1,   P53↓, 4,   P53↑, 73,   p‑P53↑, 1,   p53 Wildtype↓, 1,   p53 Wildtype↑, 1,   p53 Wildtype∅, 1,   p73↑, 1,   PARP↓, 1,   PARP↑, 19,   cl‑PARP↓, 2,   cl‑PARP↑, 51,   PARP1↑, 1,   PCNA↓, 17,   SIRT6↑, 1,   Telomerase↓, 16,   TOP1?, 1,   TOP1↓, 11,   TOP2↓, 6,   TOP2↑, 2,   TP53↑, 4,   UHRF1↓, 1,   XRCC1↓, 1,   γH2AX↓, 1,   γH2AX↑, 4,   γH2AX↝, 1,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CC(CDKs/cyclins)↓, 1,   CDK1↓, 11,   CDK1↑, 6,   CDK2↓, 30,   CDK2↑, 1,   CDK4↓, 39,   p‑CDK4↓, 1,   CDK4/6↓, 1,   CDK6↓, 11,   CDK6↑, 1,   CDK7↓, 1,   CDK8↓, 1,   CDKN1C/p57↓, 1,   CDKN1C/p57↑, 1,   CHK1↓, 2,   p‑CHK1↑, 1,   Chk2↓, 2,   ChrCon↑, 1,   Cyc↓, 1,   cycA1/CCNA1↓, 4,   cycA1/CCNA1↑, 2,   CycB/CCNB1↓, 22,   CycB/CCNB1↑, 5,   cycD1/CCND1↓, 55,   cycD1/CCND1↑, 2,   p‑cycD1/CCND1↓, 1,   CycD3↓, 1,   cycE/CCNE↓, 13,   E2Fs↓, 5,   E2Fs↑, 1,   Ki-67↓, 28,   mitA↑, 4,   p19↑, 1,   P21?, 1,   P21↓, 1,   P21↑, 44,   p27/CDKN1B↓, 2,   p27/CDKN1B↑, 17,   pRB↓, 1,   RB1↑, 1,   p‑RB1↓, 5,   Securin↓, 1,   TubPol↓, 1,   TumCCA↓, 6,   TumCCA↑, 180,   UBE2C↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 7,   ALDH1A1↓, 3,   ALDH1A3↓, 1,   Axin2↑, 1,   BMI1↓, 1,   BMP7/OP1↓, 1,   BMPs↑, 2,   CD133↓, 3,   CD133↑, 1,   CD34↓, 1,   cFos↓, 4,   cFos↑, 1,   cMYB↓, 2,   CSCs?, 1,   CSCs↓, 46,   Diff↑, 2,   EIF4E↓, 1,   FGF↓, 3,   Gli↓, 2,   Gli1↓, 9,   HH↓, 11,   HH∅, 1,   HMGCR↓, 1,   IGF-1↓, 6,   IGFBP1↑, 1,   IGFBP3↑, 1,   JAG1↓, 1,   Ki-67↓, 28,   Let-7↑, 3,   LRP6↓, 1,   mTORC1↓, 5,   Nanog↓, 12,   Nestin↓, 2,   NICD↓, 1,   NOTCH↓, 17,   NOTCH↑, 1,   NOTCH1↓, 12,   NOTCH1↑, 4,   NOTCH2↑, 1,   NOTCH3↓, 2,   p300↓, 2,   PTCH1↓, 1,   PTCH2↓, 1,   Shh↓, 8,   Smo↓, 3,   STAT1↓, 2,   TAZ↓, 1,   TumCG↓, 73,   TumCG↑, 3,   TumCP?, 1,   TumCP↓, 137,   TumCP↑, 5,   TumCP⇅, 1,   tyrosinase↓, 2,   Wnt↓, 43,   Wnt↝, 1,   Wnt/(β-catenin)↓, 2,   Zn2+↑, 1,  

Migration(tgid=13) ⓘ

AEG1↓, 1,   annexin II↓, 1,   AP-1↓, 11,   ASAP2↓, 1,   AXL↓, 1,   BACH1↓, 1,   CA↓, 1,   Ca+2↓, 3,   Ca+2↑, 18,   Ca+2↝, 2,   Cal1↑, 1,   cal2↑, 1,   Cav1↓, 1,   Cdc42↓, 1,   Cdc42↑, 1,   COL1↓, 1,   CTNNB1↓, 1,   E-cadherin↓, 9,   E-cadherin↑, 33,   EMT↓, 69,   EMT↑, 1,   EpCAM↓, 2,   FAK↓, 11,   FAK↑, 1,   p‑FAK↓, 4,   fascin↓, 1,   Fibronectin↓, 2,   GLI2↓, 1,   hnRNPA1↓, 1,   ITGB1↓, 3,   ITGB3↓, 1,   ITGB6↓, 1,   KRAS↓, 2,   LAMs↓, 2,   MALAT1↓, 3,   MET↓, 1,   MET↑, 1,   p‑MET↓, 1,   MMP-10↓, 1,   MMP1↓, 5,   MMP13↓, 4,   MMP15↓, 1,   MMP16↓, 1,   MMP2↓, 84,   MMP2↑, 1,   MMP3↓, 7,   MMP7↓, 9,   MMP9↓, 96,   MMP9↑, 4,   MMPs↓, 36,   MUC4↓, 2,   N-cadherin↓, 21,   PDGF↓, 5,   Rac1↓, 2,   RECK↑, 1,   Rho↓, 4,   Rho↑, 1,   ROCK1↓, 5,   ROCK1↑, 1,   Slug↓, 9,   Smad1↓, 1,   SMAD3↓, 1,   Snail↓, 15,   TET1?, 1,   TET1↑, 5,   TGF-β↓, 10,   TIMP1↓, 1,   TIMP1↑, 14,   TIMP2↑, 11,   TIMP3↑, 1,   TRIB3↑, 3,   TSC1↑, 1,   TumCA↓, 4,   TumCI↓, 74,   TumCMig↓, 57,   TumCMig↑, 1,   TumMeta?, 1,   TumMeta↓, 87,   TumMeta↑, 7,   TumPF↓, 1,   Twist↓, 16,   TXNIP↑, 1,   Tyro3↓, 1,   uPA↓, 14,   uPAR↓, 1,   Vim↓, 27,   Vim↑, 1,   Zeb1↓, 11,   ZEB2↓, 2,   α-SMA↓, 3,   α-SMA↑, 1,   α-tubulin↓, 2,   β-catenin/ZEB1↓, 46,   β-catenin/ZEB1↑, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 123,   angioG↑, 2,   CD31/PECAM-1↓, 7,   EGR1↑, 1,   EGR4↓, 1,   Endoglin↑, 3,   HIF-1↓, 7,   Hif1a↓, 63,   Hif1a↝, 1,   LOX1↓, 2,   NO↓, 4,   NO↑, 1,   PGI2↓, 1,   VCAM-1↓, 4,   VEGF↓, 103,   VEGF↑, 1,   VEGFR1↓, 4,   VEGFR2/KDR/Flk1↓, 8,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 17,   CLDN1↓, 4,   CLDN1↑, 1,   CX43/GJA1↓, 1,   EPR↑, 17,   GLUT1↓, 8,   GLUT1↑, 1,   GLUT3↑, 1,   GLUT4↓, 2,   IBI↑, 1,   MMP↓, 85,   MMP↑, 2,   MPT↑, 6,   NHE1↓, 2,   OATPs↓, 2,   OCLN↑, 1,   TJ↓, 1,   TJ↑, 1,   TRPV1↑, 3,   ZO-1↑, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CB2 / CNR2↑, 3,   CD4+↓, 1,   CD4+↑, 1,   CD44↓, 10,   CD47↓, 1,   CD8+↑, 2,   p‑cDC2↓, 1,   COX1↓, 2,   COX1↑, 1,   COX2/PTGS2↓, 72,   COX2/PTGS2↑, 5,   CXCL12↓, 1,   CXCR4↓, 9,   Dectin1↝, 1,   DR4↑, 5,   FOXP3↓, 2,   FOXP3↑, 1,   Gal-3↓, 1,   GM-CSF↓, 1,   HCAR1↓, 1,   HLA↑, 1,   HLA-I/II↑, 1,   HMGB1↓, 2,   ICAM-1↓, 6,   IFN-γ↓, 1,   IFN-γ↑, 3,   Igs↑, 2,   IL-1Ra↑, 1,   IL1↓, 6,   IL1↑, 1,   IL10↓, 4,   IL10↑, 3,   IL12↓, 1,   IL12↑, 1,   IL18↑, 1,   IL1R2↑, 1,   IL1RL1/ST2↑, 1,   IL1α↓, 1,   IL1β↓, 20,   IL1β↑, 1,   IL2↓, 4,   IL2↑, 7,   IL4↑, 1,   IL6↓, 39,   IL8↓, 10,   Imm↑, 20,   Imm↝, 2,   INF-γ↓, 1,   Inflam↓, 43,   IRAK1↓, 1,   LRIG1↑, 1,   pol-M1↑, 1,   M2 MC↓, 1,   MCP1/CCL2↓, 4,   MCT1↓, 2,   MDSCs↓, 1,   MIP‑1α/CCL3↓, 1,   MIP2↓, 1,   mPGES-1↓, 1,   NAF1↓, 1,   NF-kB?, 1,   NF-kB↓, 143,   NF-kB↑, 4,   p‑NF-kB↓, 1,   p‑NF-kB↑, 2,   NK cell↑, 8,   NLRP3↓, 3,   NLRP3↑, 2,   NOD1↓, 1,   p65↓, 4,   p‑p65↓, 2,   PD-1↓, 3,   PD-1↝, 2,   PD-L1↓, 11,   PGE1↓, 1,   PGE2↓, 22,   PSA↓, 14,   SOCS-3↓, 1,   T-Cell↑, 1,   TCF↓, 1,   Th1 response↑, 2,   Th17↑, 1,   TLR4↓, 5,   TLR4↝, 1,   TNF-α↓, 37,   TNF-α↑, 5,   TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, 1,   TRADD↑, 1,   Treg lymp↓, 3,  

Cellular Microenvironment(tgid=17) ⓘ

GGT/CD224↑, 1,   pH↓, 1,   pH↑, 1,   e-pH↑, 2,   i-pH↓, 1,   TAMS↓, 1,   TAMS↝, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 1,   PTN↓, 1,   SYN1↑, 1,  

Protein Aggregation(tgid=19) ⓘ

XO↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

2/16-OHE1↑, 1,   2/16-OHE1↝, 1,   ADRB2↓, 1,   AhR↓, 1,   AhR↓, 1,   AR↓, 17,   AR↝, 2,   AR-FL↓, 1,   AR-V7↑, 1,   COMT↓, 2,   CYP17A1↓, 1,   CYP19↓, 2,   ENL↑, 1,   ER(estro)↓, 2,   ERα/ESR1↓, 1,   Estro↝, 1,   FGF21↓, 1,   FKBP5↓, 1,   PPARα↓, 2,   PPARγ↓, 2,   PPARγ↑, 3,   RANKL↓, 2,   SXR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   BioAv↓, 182,   BioAv↑, 249,   BioAv⇅, 2,   BioAv↝, 80,   BioEnh?, 1,   BioEnh↑, 7,   CBR1↓, 1,   chemoR↓, 2,   ChemoSen?, 1,   ChemoSen↓, 2,   ChemoSen↑, 201,   ChemoSen⇅, 2,   CompStab?, 1,   CompStab↓, 7,   CompStab↑, 7,   CompStab↝, 3,   CYP1A1↓, 6,   CYP1A1↑, 2,   CYP1A2↓, 1,   CYP1A2↑, 2,   CYP2A3/CYP2A6↓, 1,   CYP2C9↓, 1,   CYP2E1↑, 1,   CYP3A2↓, 1,   CYP3A4↓, 5,   DDS↑, 10,   Dose?, 5,   Dose↓, 4,   Dose↑, 16,   Dose↝, 91,   Dose∅, 11,   DrugR↓, 1,   eff?, 1,   eff↓, 28,   eff↑, 134,   eff⇅, 1,   eff↝, 15,   eff∅, 3,   GSTA1↑, 2,   GSTM1↑, 1,   GSTZ1↓, 1,   GSTZ1↝, 1,   Half-Life↓, 33,   Half-Life↑, 12,   Half-Life↝, 38,   Half-Life∅, 5,   MDR1↓, 10,   MRP↓, 1,   MRP1/ABCC1↓, 5,   MRP1/ABCC1↑, 1,   MRP1/ABCC1↝, 1,   P-gp/ABCB1↓, 22,   P-gp/ABCB1↑, 3,   P-gp/ABCB1⇅, 1,   P450↓, 5,   RadioS?, 1,   RadioS↑, 72,   RadioS↝, 1,   selectivity?, 1,   selectivity↑, 91,   selectivity↝, 2,   selectivity∅, 1,   Synergy?, 1,   Synergy↑, 122,   Synergy↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AFP↓, 1,   ALAT↓, 6,   ALAT↑, 1,   ALP↓, 2,   AR↓, 17,   AR↝, 2,   ascitic↓, 1,   AST↓, 4,   AST↑, 1,   BMD↑, 1,   BP↓, 2,   BRAF↓, 1,   BRCA1↓, 2,   p‑BRCA1↑, 1,   CEA↓, 2,   CEC↝, 1,   CRP↓, 2,   E6↓, 2,   E7↓, 2,   EGFR↓, 31,   EGFR↑, 2,   p‑EGFR↓, 1,   ERα/ESR1↓, 1,   EZH2↓, 5,   Ferritin↓, 1,   FOXM1↓, 4,   HER2/EBBR2↓, 8,   hTERT/TERT↓, 14,   IL6↓, 39,   KRAS↓, 2,   LDH↓, 5,   LDH↑, 1,   LDH↝, 1,   Myc↓, 5,   NOS2↓, 1,   NOS2↑, 1,   NSE↓, 1,   PD-L1↓, 11,   Polyps↓, 1,   PSA↓, 14,   PSADT↑, 1,   TF-Ag↓, 1,   TG/TAG↓, 1,   TP53↑, 4,   TRIB3↑, 3,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 2,   AntiArt↑, 1,   AntiCan↓, 3,   AntiCan↑, 81,   AntiCan∅, 1,   antiD↑, 1,   AntiDiabetic↑, 1,   antiNeop↑, 4,   antiPs↑, 1,   AntiTum↑, 29,   cachexia↓, 3,   cardioP↑, 22,   CardioT↓, 1,   CardioT↑, 1,   chemoP↑, 45,   chemoPv↑, 25,   ChemoSideEff↓, 7,   cognitive?, 1,   cognitive↑, 4,   fatigue↓, 2,   hepatoP↓, 3,   hepatoP↑, 14,   memory↑, 4,   Mucositis↓, 1,   neuroP↑, 13,   NP/CIPN↓, 3,   NP/CIPN↑, 1,   Obesity↓, 1,   ORR↑, 1,   OS↑, 18,   OS↝, 1,   OS∅, 1,   Pain↓, 5,   PFS↓, 1,   PFS↑, 1,   PFS∅, 1,   QoL↑, 5,   QoL↝, 1,   radioP↑, 10,   Remission↑, 2,   RenoP↑, 8,   Risk↓, 34,   Risk↑, 1,   Sleep↑, 1,   toxicity↓, 40,   toxicity↑, 8,   toxicity⇅, 2,   toxicity↝, 22,   toxicity∅, 4,   TumVol↓, 22,   TumW↓, 7,   Weight↑, 1,   Wound Healing↑, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↓, 1,   AntiBio↑, 2,   AntiViral↑, 1,   Bacteria↓, 4,   Dectin1↝, 1,   GutMicro↑, 12,   GutMicro↝, 1,   Sepsis↓, 3,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr?, 3,   Ingr↝, 9,  
Total Targets: 1077

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

NA↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

4-HNE↓, 1,   antiOx?, 1,   antiOx↓, 16,   antiOx↑, 191,   ARE↑, 4,   ARE↝, 1,   Catalase↓, 1,   Catalase↑, 69,   Fenton↓, 2,   GPx↓, 1,   GPx↑, 54,   GPx1↑, 2,   GPx4↑, 1,   GSH↓, 1,   GSH↑, 66,   GSR↑, 9,   GSTs↓, 3,   GSTs↑, 18,   H2O2↓, 7,   H2O2↑, 1,   H2O2∅, 2,   HDL↑, 5,   HDL∅, 1,   HNE↓, 1,   HO-1↓, 2,   HO-1↑, 47,   HO-2↓, 1,   Iron↓, 1,   Keap1↓, 2,   Keap1↑, 2,   Keap1↝, 1,   lipid-P↓, 58,   mt-lipid-P↓, 1,   MDA↓, 52,   MPO↓, 12,   NADH↓, 1,   NOX↓, 1,   NQO1↑, 11,   NQO1↝, 1,   NQO1∅, 1,   Nrf1↑, 2,   NRF2?, 1,   NRF2↓, 3,   NRF2↑, 76,   NRF2⇅, 1,   NRF2↝, 1,   Prx↑, 1,   RNS↓, 5,   ROS?, 1,   ROS↓, 226,   ROS↑, 5,   ROS⇅, 5,   ROS∅, 2,   mt-ROS?, 1,   selenoP↑, 4,   SOD↓, 5,   SOD↑, 98,   mt-SOD↑, 1,   SOD1↑, 5,   SOD2↑, 3,   TAC↑, 7,   TBARS↓, 2,   Thiols↑, 1,   Trx↑, 2,   Trx1↑, 1,   TrxR↑, 1,   uricA↓, 3,   VitC↑, 5,   VitE↑, 4,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↓, 1,   Ferritin↑, 1,   FPN↑, 1,   IronCh↑, 13,   IronCh↝, 1,   Mets↝, 1,   TfR1/CD71↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

compI↑, 2,   compII↑, 2,   compIII↑, 2,   compIV↑, 1,   DRP1/DNM1L↓, 1,   ETC↑, 1,   Insulin↓, 2,   Insulin↑, 4,   Insulin↝, 1,   MFN2↑, 1,   mtDam↓, 4,   OCR↓, 1,   OCR↑, 2,   OXPHOS↑, 1,   PGC-1α↑, 4,   PGC-1α↝, 1,   PINK1↑, 1,   SIRT3↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 2,   15-LOX/ALOX15↓, 1,   5LO↓, 5,   ACC↓, 1,   Acetyl-CoA↑, 1,   adiP↑, 1,   ALAT↓, 18,   ALAT∅, 2,   AMPK↓, 2,   AMPK↑, 16,   AMPK↝, 1,   ATP↓, 1,   ATP↑, 11,   Buty↑, 1,   cAMP↑, 2,   CRM↑, 1,   cytoP450↓, 1,   DHODH↓, 1,   FABP4↓, 1,   FAO↑, 1,   FASN↓, 1,   FFA/NEFA↓, 1,   G6PD↑, 1,   glucose↓, 8,   glucose↝, 4,   GlucoseCon↑, 5,   GlutMet↑, 1,   glyC↓, 1,   Glycolysis↓, 1,   GSK‐3β↓, 13,   GSK‐3β↑, 3,   p‑GSK‐3β↑, 1,   H2S↑, 1,   HMG-CoA↓, 2,   LDHA↑, 1,   LDL↓, 16,   lipidLev↓, 6,   lipoGen↓, 1,   NAD↓, 1,   NAD↑, 2,   NADH:NAD↑, 1,   NADPH↓, 3,   NADPH↑, 4,   PDK1 / PDPK1↓, 1,   PFK↓, 1,   PLA2↓, 2,   SCFAs↑, 1,   SIRT1↑, 21,   SIRT1↝, 1,   SIRT2↑, 1,   SREBF2↓, 1,   SREBF2⇅, 1,   SREBP1/SREBF1↓, 1,   SREBP1/SREBF1↑, 1,  

Cell Death(tgid=5) ⓘ

AIF↓, 1,   Apoptosis↓, 15,   ASC↓, 1,   BAX↓, 12,   Bax:Bcl2↓, 2,   Bcl-2↓, 3,   Bcl-2↑, 9,   Casp1↓, 1,   Casp12↓, 1,   Casp3↓, 25,   cl‑Casp3↓, 1,   Casp6↓, 1,   Casp8↓, 1,   Casp9↓, 11,   Casp9↑, 1,   Cyt‑c↓, 5,   Cyt‑c∅, 1,   Fas↓, 1,   Ferroptosis↓, 2,   GranB/GZMB↓, 1,   iNOS↓, 27,   iNOS↑, 1,   necrosis↓, 1,   p38↓, 3,   Pyro↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 5,   Akt↑, 19,   Akt↝, 1,   p‑Akt↓, 1,   p‑Akt↑, 3,   Akt2↓, 1,   AMPKα↑, 1,   CREB↑, 5,   p‑CREB↑, 1,   ERK↓, 6,   ERK↑, 5,   p‑ERK↑, 3,   HGF/c-Met↑, 1,   IGF-1R↓, 1,   IKKα↓, 2,   JAK↓, 2,   JAK2↓, 1,   JAK2↑, 1,   JNK↓, 7,   p‑JNK↓, 3,   MAPK↓, 17,   MAPK↑, 2,   MAPK↝, 2,   mTOR↓, 3,   mTOR↑, 5,   mTOR↝, 1,   P70S6K↓, 1,   PDGFR-BB↓, 1,   PI3K↓, 5,   PI3K↑, 10,   PI3K↝, 1,   PKCδ↓, 2,   PKCδ↑, 2,   PP2A↑, 1,   PTEN↓, 2,   PTEN↑, 1,   STAT↓, 2,   STAT3↓, 3,   STAT3↑, 3,   p‑STAT3↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

Ac-histone H3↑, 1,   AntiThr↑, 8,   ATF2↑, 1,   ATF4↓, 3,   DNMT1↓, 1,   FOXO↑, 1,   FOXO3↑, 1,   H3↑, 1,   H4↑, 1,   HATs↓, 1,   HDAC↓, 3,   HDAC↑, 2,   HDAC1↓, 1,   HDAC2↓, 1,   HDAC3↓, 2,   HOTAIR↑, 1,   other?, 3,   other↓, 10,   other↑, 26,   other↝, 43,   PhotoS↑, 1,   SOX2↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 4,   CHOP/DDIT3↑, 1,   eIF2α↓, 1,   p‑eIF2α↓, 1,   ER Stress↓, 7,   GRP78/BiP↓, 4,   GRP78/BiP↑, 2,   GRP94↑, 1,   HSP70/HSPA5↑, 3,   HSP70/HSPA5↝, 1,   HSP90↑, 1,   HSPs↑, 2,   IRE1↓, 1,   PERK↓, 1,   UPR↑, 1,   XBP-1↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↓, 5,   Beclin-1/ATG6↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3II↓, 2,   LC3II↑, 1,   MitoP↓, 1,   p62↑, 1,   PARK2↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

p‑BRCA1↑, 1,   DNAdam↓, 13,   DNArepair↑, 3,   P53↓, 3,   PARP1↓, 1,   PCNA↓, 2,   Telomerase↓, 1,   TOP1↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 1,   cycE/CCNE↓, 1,   E2Fs↑, 1,   GADD34↓, 1,   Ki-67↓, 2,   Ki-67↑, 1,   P21↓, 1,   RB1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑4E-BP1↓, 1,   CEBPA↓, 1,   Choline↑, 2,   Diff↝, 1,   FGF↑, 1,   GH↑, 1,   HH↓, 1,   HMGCR↓, 1,   IGF-1↓, 1,   IGF-1↑, 1,   IGFBP3↑, 1,   Ki-67↓, 2,   Ki-67↑, 1,   Nestin↑, 1,   neuroG↑, 8,   NOTCH1↑, 1,   TumCP↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↓, 3,   AntiAg↑, 26,   AP-1↓, 7,   BACH1↓, 1,   Ca+2↓, 3,   Ca+2↑, 2,   Ca+2↝, 1,   Cartilage↑, 2,   COL1↓, 3,   Fibrosis↓, 1,   LRP1↑, 1,   MLC2/MYL9↝, 1,   MMP13↓, 2,   MMP2↓, 2,   MMP2↑, 2,   MMP3↓, 1,   MMP9↓, 10,   MMPs↓, 4,   MUC1↑, 1,   N-cadherin↑, 1,   Rho↓, 1,   ROCK1↓, 1,   p‑SMAD2↓, 2,   p‑SMAD3↓, 1,   p‑SMAD3↑, 1,   p‑T-cadherin↓, 1,   TGF-β↓, 5,   TGF-β↑, 2,   TGF-β1↓, 2,   TGF-β1↑, 1,   TIMP1↓, 1,   TregCell↑, 1,   TXNIP↓, 1,   uPA↑, 1,   α-SMA↓, 4,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   angioG↑, 3,   CD31/PECAM-1↑, 1,   E-sel↓, 1,   NO↓, 21,   NO↑, 3,   TXA2↓, 2,   VCAM-1↓, 8,   VEGF↓, 2,   VEGF↑, 3,  

Barriers & Transport(tgid=15) ⓘ

BBB?, 1,   BBB↓, 8,   BBB↑, 53,   BBB↝, 3,   BBB∅, 3,   EPR↑, 1,   GastroP↑, 7,   GLUT2↑, 2,   GLUT3↑, 1,   GLUT4↑, 3,   H+/K+-ATPase↓, 1,   IBI↑, 5,   memfluid↑, 2,   MMP↓, 1,   MMP↑, 16,   MMP∅, 1,   MUC19↓, 1,   MUC2↓, 1,   OCLN↓, 1,   OCLN↝, 1,   TJ↑, 3,   TRPA1↑, 1,   TRPV1↑, 2,   TRPV3↑, 2,   VGSC↓, 1,   ZO-1↓, 1,   ZO-1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

AIF1/Iba-1↓, 1,   CB2 / CNR2↑, 1,   CD4+↑, 2,   CD40↓, 1,   CD8+↑, 1,   COX1↓, 9,   COX2/PTGS2↓, 57,   COX2/PTGS2↑, 1,   CXCR4↓, 1,   HMGB1↓, 2,   ICAM-1↓, 5,   IFN-γ↓, 5,   IFN-γ↑, 1,   IL1↓, 5,   IL10↓, 6,   IL10↑, 6,   IL12↓, 2,   IL17↓, 4,   IL18↓, 3,   IL1α∅, 1,   IL1β↓, 48,   IL1β∅, 1,   IL2↓, 5,   IL22↓, 1,   IL33↓, 1,   IL4↓, 5,   IL4↑, 1,   IL5↓, 2,   IL6↓, 56,   IL6↑, 3,   IL8↓, 12,   IL8↑, 1,   IL8∅, 1,   Imm↓, 2,   Imm↑, 20,   Imm⇅, 1,   Imm↝, 2,   INF-γ↓, 1,   Inflam?, 1,   Inflam↓, 221,   Inflam↑, 6,   IP-10/CXCL-10↓, 1,   IRF3↓, 1,   LPS↓, 1,   pol-M2 MC↑, 1,   MCP1/CCL2↓, 5,   MCP1/CCL2↑, 1,   MCP1/CCL2∅, 1,   MCT1↓, 1,   MIP‑1α/CCL3↓, 1,   MyD88↓, 1,   NeuroI↓, 4,   NF-kB↓, 77,   NF-kB↑, 3,   p‑NF-kB↓, 1,   NLRP3↓, 14,   NLRP3↑, 2,   p65↓, 2,   PGE2↓, 19,   RAGE↓, 3,   RANTES↓, 1,   TLR2↓, 4,   TLR3↓, 1,   TLR4↓, 9,   TLR4↑, 1,   TNF-α↓, 81,   TNF-α↑, 2,   VitD↑, 1,  

Cellular Microenvironment(tgid=17) ⓘ

GFAP↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 1,   5HT↑, 6,   Ach↑, 6,   AChE↓, 30,   AChE↑, 2,   ADAM10↑, 3,   BChE↓, 9,   BDNF↓, 1,   BDNF↑, 20,   ChAT↑, 6,   GABA↑, 5,   MAOA↓, 6,   MAOA↝, 1,   MAOB↓, 2,   monoA↑, 1,   NGF↑, 6,   PSD95↑, 4,   SNAP25↑, 2,   TPH1↓, 1,   TrkB↑, 4,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 7,   APOE4↓, 1,   APP↓, 6,   cl‑APP↑, 1,   Aβ↓, 54,   Aβ42↓, 4,   BACE/β-secretase↓, 15,   PSEN1/PS1↑, 1,   tau↓, 16,   p‑tau↓, 7,   XO↓, 1,   XO↝, 1,   β-Amyloid↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ACE/ACE1↓, 1,   ACE2↓, 1,   cortisol↑, 1,   CYP19↓, 2,   DHT↑, 1,   GLP-1R↑, 1,   GR↑, 1,   PPARα↑, 4,   PPARγ↓, 3,   PPARγ↑, 8,   p‑PPARγ↓, 1,   SHBG↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABC↓, 1,   BioAv?, 2,   BioAv↓, 214,   BioAv↑, 368,   BioAv⇅, 4,   BioAv↝, 179,   BioAv∅, 3,   BioEnh↑, 6,   ChemoSen↑, 4,   CompStab↓, 1,   CompStab↑, 10,   CompStab↝, 3,   CYP1A1↑, 1,   CYP1A2↑, 1,   CYP2E1↓, 2,   CYP3A2↓, 1,   DDS↑, 1,   Dose?, 6,   Dose↑, 9,   Dose⇅, 2,   Dose↝, 121,   Dose∅, 4,   eff↓, 5,   eff↑, 63,   eff↝, 7,   GSTA1↓, 1,   GSTA1↑, 1,   Half-Life?, 2,   Half-Life↓, 34,   Half-Life↑, 19,   Half-Life↝, 65,   Half-Life∅, 6,   MRP1/ABCC1↓, 1,   P-gp/ABCB1↓, 7,   P450↓, 3,   P450↑, 2,   P450↝, 1,   Synergy↑, 34,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 18,   ALAT∅, 2,   ALB↑, 1,   ALP↓, 4,   anemia↓, 1,   AST↓, 20,   AST∅, 2,   BG↓, 2,   BloodF↑, 8,   BMD↑, 5,   BP↓, 17,   BP↝, 1,   p‑BRCA1↑, 1,   creat↓, 4,   CRP↓, 8,   Ferritin↓, 1,   Ferritin↑, 1,   HemoG↑, 1,   HOMA↓, 1,   hs-CRP↓, 3,   IL6↓, 56,   IL6↑, 3,   IRes↓, 1,   IRes↑, 2,   IRes↝, 1,   LDH↓, 6,   NOS2↓, 2,   RAGE↓, 3,   RBC↑, 1,   TC↓, 3,   TG/TAG↓, 2,   TMAO↓, 1,   Urea↓, 2,   VitD↑, 1,  

Functional Outcomes(tgid=23) ⓘ

Analgesic↑, 5,   AntiAge↑, 12,   antiAll↑, 20,   AntiArt↑, 8,   AntiCan↓, 1,   AntiCan↑, 37,   antiCG↝, 1,   AntiDiabetic↓, 2,   AntiDiabetic↑, 48,   AntiMyl↑, 1,   antiPs↑, 4,   AntiTum↓, 2,   AntiTum↑, 6,   Appetite↓, 1,   BowelM↑, 1,   cardioP↓, 2,   cardioP↑, 97,   cardioP⇅, 1,   CardioT↓, 2,   chemoP↑, 15,   chemoPv↑, 13,   cognitive↓, 2,   cognitive↑, 79,   cognitive↝, 1,   cognitive∅, 2,   cough?, 1,   diuretic↑, 3,   hepatoP↓, 3,   hepatoP↑, 69,   Learn↑, 5,   memory↓, 1,   memory↑, 62,   motorD↓, 1,   motorD↑, 10,   Mucositis↓, 2,   neuroP↓, 2,   neuroP↑, 171,   neuroP↝, 1,   Obesity↓, 27,   OS↑, 4,   Pain↓, 11,   radioP↑, 9,   RenoP↓, 1,   RenoP↑, 20,   RenoP↝, 1,   Risk↓, 6,   Risk↑, 3,   Sleep↑, 2,   SoreThr?, 1,   Strength↑, 2,   Stroke↓, 17,   toxicity?, 2,   toxicity↓, 76,   toxicity↑, 13,   toxicity⇅, 1,   toxicity↝, 29,   toxicity∅, 12,   Weight↓, 4,   Weight↝, 1,   Wound Healing↑, 8,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↑, 21,   AntiFungal↑, 7,   AntiP↑, 1,   AntiViral↑, 17,   Bacteria↓, 42,   Diar↓, 2,   GutMicro↑, 40,   GutMicro↝, 2,   Sepsis↓, 4,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr?, 1,   Ingr↑, 6,   Ingr↝, 11,  
Total Targets: 626

Scientific Paper Hit Count for: BioAv, bioavailability
49 Curcumin
27 Sulforaphane (mainly Broccoli)
20 chitosan
20 Quercetin
20 EGCG (Epigallocatechin Gallate)
18 Baicalein
18 Chlorogenic acid
17 Resveratrol
15 Berberine
15 Selenium NanoParticles
15 Chrysin
15 Luteolin
15 Lycopene
14 Apigenin (mainly Parsley)
14 Pterostilbene
13 Kaempferol
12 Thymoquinone
11 Phenethyl isothiocyanate
11 Silymarin (Milk Thistle) silibinin
11 Honokiol
10 Alpha-Lipoic-Acid
10 Rosmarinic acid
10 Magnolol
9 Astaxanthin
9 borneol
9 Carvacrol
9 Morin
9 Urolithin
8 Allyl isothiocyanate
8 Broccoli
8 Capsaicin
8 Crocetin
8 Piperine
8 Diindolylmethane
8 Emodin
8 Ferulic acid
8 Fucoidan
8 Piperlongumine
7 Silver-NanoParticles
7 Allicin (mainly Garlic)
7 Artemisinin
7 Betulinic acid
7 Hydroxycinnamic-acid
7 Fisetin
7 Flaxseed/Linseed
7 HydroxyTyrosol
7 Isoliquiritigenin
7 isoquercitrin
6 Ashwagandha(Withaferin A)
6 Biochanin A
6 Rutin
6 Propolis -bee glue
6 Ellagic acid
6 Eugenol
5 beta-glucans
5 Baicalin
5 Boswellia (frankincense)
5 Thymol-Thymus vulgaris
5 Centella asiatica / Gotu kola → asiaticoside
5 Cucurbitacin
5 Formononetin
5 SDG/lignans
5 Gallic acid
5 Inositol
5 Isothiocyanates
5 Naringin
5 Selenite (Sodium)
4 1,8-Cineole
4 5-Hydroxytryptophan
4 Beta-Caryophyllene
4 Benzyl isothiocyanate
4 Boron
4 Caffeic acid
4 Melatonin
4 Celastrol
4 phytic acid, Inositol hexakisphosphate
4 Garcinol
4 Isovitexin
4 Lactoferrin/Talactoferrin
4 Matrine
4 Phenylbutyrate
4 Phycocyanin
4 Vitamin C (Ascorbic Acid)
4 Shikonin
4 Aflavin-3,3′-digallate
3 Ascorbyl Palmitate
3 Gold NanoParticles
3 Berbamine
3 Folic Acid, Vit B9
3 Chocolate
3 Cinnamon
3 Coenzyme Q10
3 Copper and Cu NanoParticles
3 Diclofenac
3 Indole-3-carbinol
3 Disulfiram
3 Fenbendazole
3 Gambogic Acid
3 Genistein (soy isoflavone)
3 Glabrescione B
3 Gossypol/AT-101
3 Grapeseed extract
3 Lapatinib
3 Licochalcone A
3 Licorice
3 Lecithin
3 Linalool
3 Lutein
3 Methylene blue
3 mebendazole
3 Metformin
3 Magnetic Fields
3 Mangiferin
3 Niclosamide (Niclocide)
3 Selenium
3 Silicic Acid
3 Spermidine
3 Terpinen-4-ol / Tea Tree Oil
2 3-bromopyruvate
2 Auranofin
2 Astragalus
2 Citric Acid
2 Aspirin
2 Paclitaxel/Taxol
2 Atorvastatin
2 immunotherapy
2 doxorubicin
2 Docetaxel
2 Radiotherapy/Radiation
2 buckwheat sprouts
2 Butyrate
2 Cynanbungeigenin C (CBC) and D (CBD)
2 Chlorophyllin
2 Choline
2 Camptothecin
2 Cynara scolymus/Globe Artichoke/Artichoke Extract
2 Dasatinib/Phyrago
2 Dichloroacetate
2 Deguelin
2 D-limonene
2 Evodiamine
2 flavonoids
2 MCT oil
2 Shilajit/Fulvic Acid
2 Geraniol
2 Ginkgolide B
2 Ginkgetin
2 Hydrogen Gas
2 HydroxyCitric Acid
2 Isorhamnetin
2 isoflavones
2 isoorientin
2 itraconazole
2 Ivermectin
2 L-Theanine
2 Lapachol
2 Lemongrass Extract/Citral
2 Methyl salicylate / Sweet Birch oil
2 magnetic nanoparticles
2 Magnesium
2 Mushroom Lion’s Mane, Hericium erinaceus
2 nicotinamide adenine dinucleotide
2 Oleuropein
2 Turmerones
2 Ursolic acid
1 Açaí, Euterpe oleracea
1 Aluminum
1 Anethole/trans-Anethole
1 Aromatherapy
1 Gemcitabine (Gemzar)
1 Aloe anthraquinones
1 xanthohumol
1 beta-carotene(VitA)
1 Bicalutamide
1 Bacopa monnieri
1 α-Bisabolol / Chamomile oil
1 Black turtle bean
1 Bullatacin
1 Carnosic acid
1 urea
1 capecitabine
1 Catechins
1 Cat’s Claw
1 Cannabidiol
1 Zinc
1 Citicoline, CDP-Choline
1 irinotecan
1 Cranberry
1 Polyphenols
1 Chlorella (Chlorella vulgaris)
1 Cyclopamine
1 Dichloroacetophenone(2,2-)
1 Dandelion Root
1 Echinacea
1 Ginkgo biloba-EGb 761
1 Electrical Pulses
1 Eurycomanone
1 Sesame seeds and Oil
1 Mung Bean Sprouts
1 tamoxifen
1 Gamma-aminobutyric acid
1 Ginkgo biloba
1 Germanium Organic/Ge-132 / propagermanium (organogermanium)
1 Geldanamycin
1 Ginger/6-Shogaol/Gingerol
1 Ginseng
1 Arsenic trioxide
1 Graviola
1 Germacranolide sesquiterpene lactone
1 Hibiscus sabdariffa
1 Hyperthermia
1 Huperzine A/Huperzia serrata
1 Hyperoside
1 Isobavachalcone
1 iodine
1 Anthocyanins
1 Modified Citrus Pectin
1 Moringin
1 Mushroom Maitake
1 Bicarbonate(Sodium)
1 Oleocanthal
1 Oxygen, Hyperbaric
1 Patchouli Oil (Pogostemon cablin)
1 Cisplatin
1 Propranolol
1 Psoralidin
1 Psyllium husk
1 Parthenolide
1 enzalutamide
1 Rauwolfia serpentina/Indian Snakeroot
1 salinomycin
1 Chemotherapy
1 Date Fruit Extract
1 Spirulina(Arthrospira/Limnospira)
1 cetuximab
1 Tomatine
1 Vitamin B3,Niacin
1 Vitamin D3
1 Vitamin E
1 Vitamin K2
1 Vitexin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:792  State#:%  Dir#:%
wNotes=on sortOrder:rid,rpid

 

Home Page